1
|
Haryuni RD, Nukui T, Piao JL, Shirakura T, Matsui C, Sugimoto T, Baba K, Nakane S, Nakatsuji Y. Elevated Serum Xanthine Oxidase and Its Correlation with Antioxidant Status in Patients with Parkinson's Disease. Biomolecules 2024; 14:490. [PMID: 38672506 PMCID: PMC11048637 DOI: 10.3390/biom14040490] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2024] [Revised: 04/13/2024] [Accepted: 04/16/2024] [Indexed: 04/28/2024] Open
Abstract
Parkinson's disease (PD) is a neurodegenerative movement disorder associated with a loss of dopamine neurons in the substantia nigra. The diagnosis of PD is sensitive since it shows clinical features that are common with other neurodegenerative diseases. In addition, most symptoms arise at the late stage of the disease, where most dopaminergic neurons are already damaged. Several studies reported that oxidative stress is a key modulator in the development of PD. This condition occurs due to excess reactive oxygen species (ROS) production in the cellular system and the incapability of antioxidants to neutralize it. In this study, we focused on the pathology of PD by measuring serum xanthine oxidase (XO) activity, which is an enzyme that generates ROS. Interestingly, the serum XO activity of patients with PD was markedly upregulated compared to patients with other neurological diseases (ONDs) as a control. Moreover, serum XO activity in patients with PD showed a significant correlation with the disease severity based on the Hoehn and Yahr (HY) stages. The investigation of antioxidant status also revealed that serum uric acid levels were significantly lower in the severe group (HY ≥ 3) than in the ONDs group. Together, these results suggest that XO activity may contribute to the development of PD and might potentially be a biomarker for determining disease severity in patients with PD.
Collapse
Affiliation(s)
- Ratna Dini Haryuni
- Department of Neurology, Faculty of Medicine, University of Toyama, Toyama 930-8555, Japan (T.N.); (J.-L.P.); (S.N.)
- Research Center for Radioisotope, Radiopharmaceutical, and Biodosimetry Technology, National Research and Innovation Agency, Jakarta 10340, Indonesia
| | - Takamasa Nukui
- Department of Neurology, Faculty of Medicine, University of Toyama, Toyama 930-8555, Japan (T.N.); (J.-L.P.); (S.N.)
| | - Jin-Lan Piao
- Department of Neurology, Faculty of Medicine, University of Toyama, Toyama 930-8555, Japan (T.N.); (J.-L.P.); (S.N.)
| | - Takashi Shirakura
- Teijin Institute for Bio-Medical Research, Teijin Pharma Ltd., Tokyo 191-8512, Japan; (T.S.)
| | - Chieko Matsui
- Teijin Institute for Bio-Medical Research, Teijin Pharma Ltd., Tokyo 191-8512, Japan; (T.S.)
| | - Tomoyuki Sugimoto
- Faculty of Data Science, Graduate School of Data Science, University of Shiga, 1-1-1 Banba, Hikone 522-8533, Japan;
| | - Kousuke Baba
- Department of Neurology, Faculty of Medicine, University of Toyama, Toyama 930-8555, Japan (T.N.); (J.-L.P.); (S.N.)
| | - Shunya Nakane
- Department of Neurology, Faculty of Medicine, University of Toyama, Toyama 930-8555, Japan (T.N.); (J.-L.P.); (S.N.)
| | - Yuji Nakatsuji
- Department of Neurology, Faculty of Medicine, University of Toyama, Toyama 930-8555, Japan (T.N.); (J.-L.P.); (S.N.)
| |
Collapse
|
2
|
Seki T, Baba K, Hayashi T, Furuta R, Hirosawa H, Mitsui T, Maesaka H, Takasawa S, Miwa T, Tanaka K, Nakatsuji Y. Lung Cancer Wherein Durvalumab Induced Both Anti-CRMP-5 Antibody-related Paraneoplastic Neurological Syndromes and Neurological Adverse Events. Intern Med 2024; 63:1009-1014. [PMID: 37612090 PMCID: PMC11045384 DOI: 10.2169/internalmedicine.1771-23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/13/2023] [Accepted: 07/17/2023] [Indexed: 08/25/2023] Open
Abstract
A 68-year-old man with small-cell lung cancer developed anti-collapsin response-mediator protein (CRMP)-5 antibody-related paraneoplastic neurological syndrome (PNS) presenting with ataxia and chorea during treatment with durvalumab. As a result of steroid therapy, anti-CRMP-5 antibodies became negative, hyperintense lesions on brain magnetic resonance imaging disappeared, and neurological symptoms improved. After resuming durvalumab, he became unable to walk due to neurological adverse events (nAEs). There have been no reported cases manifesting PNSs and nAEs as a result of the same immune checkpoint inhibitors (ICIs) administered at different times. Resuming ICIs in patients diagnosed with PNSs should be performed with prudence.
Collapse
Affiliation(s)
- Tomokazu Seki
- Department of Neurology, Faculty of Medicine, University of Toyama, Japan
| | - Kousuke Baba
- Department of Neurology, Faculty of Medicine, University of Toyama, Japan
| | - Tomohiro Hayashi
- Department of Neurology, Faculty of Medicine, University of Toyama, Japan
| | - Risako Furuta
- Department of Neurology, Faculty of Medicine, University of Toyama, Japan
| | - Hiroaki Hirosawa
- Department of Neurology, Faculty of Medicine, University of Toyama, Japan
| | - Taichi Mitsui
- Department of Neurology, Faculty of Medicine, University of Toyama, Japan
| | - Hiroki Maesaka
- Department of Neurology, Faculty of Medicine, University of Toyama, Japan
| | - Syuhei Takasawa
- Department of Neurology, Faculty of Medicine, University of Toyama, Japan
| | - Toshiro Miwa
- First Department of Internal Medicine, Toyama University Hospital, Japan
| | - Keiko Tanaka
- Department of Animal Model Development, Bioresource Science Branch, Center for Bioresource-based Research, Brain Research Institute, Niigata University, Japan
| | - Yuji Nakatsuji
- Department of Neurology, Faculty of Medicine, University of Toyama, Japan
| |
Collapse
|
3
|
Shibuya R, Baba K, Furuta R, Maesaka H, Hirosawa H, Bando T, Oshima A, Onoda H, Nukui T, Dougu N, Joho S, Nakatsuji Y. A Case of Liver Cancer with Overlapping Myasthenia Gravis, Myocarditis, Seronegative Autoimmune Autonomic Ganglionopathy, and Myositis Symptoms Induced by Atezolizumab: A Case Report. Intern Med 2024:1801-23. [PMID: 38171860 DOI: 10.2169/internalmedicine.1801-23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/05/2024] Open
Abstract
An 83-year-old man with hepatocellular carcinoma developed muscle weakness, ptosis, and dyspnea 3 weeks after receiving atezolizumab. Soon after, mechanical ventilation was initiated, which was followed by marked blood pressure spikes. The levels of creatine kinase and troponin-I were significantly elevated, and acetylcholine receptor antibodies were positive. The patient was diagnosed with immune checkpoint inhibitor (ICI)-induced myositis, myasthenia gravis (MG), myocarditis, and suspected autoimmune autonomic ganglionopathy (AAG). After immunotherapy, the serum markers and blood pressure normalized, and he was weaned from the ventilator after five months. To our knowledge, this is the first reported case of AAG secondary to ICI-induced myositis, MG, and myocarditis.
Collapse
Affiliation(s)
- Ryoko Shibuya
- Department of Neurology, Faculty of Medicine, University of Toyama, Japan
| | - Kousuke Baba
- Department of Neurology, Faculty of Medicine, University of Toyama, Japan
| | - Risako Furuta
- Department of Neurology, Faculty of Medicine, University of Toyama, Japan
| | - Hiroki Maesaka
- Department of Neurology, Faculty of Medicine, University of Toyama, Japan
| | - Hiroaki Hirosawa
- Department of Neurology, Faculty of Medicine, University of Toyama, Japan
| | - Tadashi Bando
- Department of Surgery, Saiseikai Toyama Hospital, Japan
| | - Akira Oshima
- Second Department of Internal Medicine, Faculty of Medicine, University of Toyama, Japan
| | - Hiroshi Onoda
- Second Department of Internal Medicine, Faculty of Medicine, University of Toyama, Japan
| | - Takamasa Nukui
- Department of Neurology, Faculty of Medicine, University of Toyama, Japan
| | - Nobuhiro Dougu
- Department of Neurology, Faculty of Medicine, University of Toyama, Japan
| | - Shuji Joho
- Second Department of Internal Medicine, Faculty of Medicine, University of Toyama, Japan
| | - Yuji Nakatsuji
- Department of Neurology, Faculty of Medicine, University of Toyama, Japan
| |
Collapse
|
4
|
Kakuda K, Ikenaka K, Kuma A, Doi J, Aguirre C, Wang N, Ajiki T, Choong CJ, Kimura Y, Badawy SMM, Shima T, Nakamura S, Baba K, Nagano S, Nagai Y, Yoshimori T, Mochizuki H. Lysophagy protects against propagation of α-synuclein aggregation through ruptured lysosomal vesicles. Proc Natl Acad Sci U S A 2024; 121:e2312306120. [PMID: 38147546 PMCID: PMC10769825 DOI: 10.1073/pnas.2312306120] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2023] [Accepted: 11/21/2023] [Indexed: 12/28/2023] Open
Abstract
The neuron-to-neuron propagation of misfolded α-synuclein (αSyn) aggregates is thought to be key to the pathogenesis of synucleinopathies. Recent studies have shown that extracellular αSyn aggregates taken up by the endosomal-lysosomal system can rupture the lysosomal vesicular membrane; however, it remains unclear whether lysosomal rupture leads to the transmission of αSyn aggregation. Here, we applied cell-based αSyn propagation models to show that ruptured lysosomes are the pathway through which exogenous αSyn aggregates transmit aggregation, and furthermore, this process was prevented by lysophagy, i.e., selective autophagy of damaged lysosomes. αSyn aggregates accumulated predominantly in lysosomes, causing their rupture, and seeded the aggregation of endogenous αSyn, initially around damaged lysosomes. Exogenous αSyn aggregates induced the accumulation of LC3 on lysosomes. This LC3 accumulation was not observed in cells in which a key regulator of autophagy, RB1CC1/FIP200, was knocked out and was confirmed as lysophagy by transmission electron microscopy. Importantly, RB1CC1/FIP200-deficient cells treated with αSyn aggregates had increased numbers of ruptured lysosomes and enhanced propagation of αSyn aggregation. Furthermore, various types of lysosomal damage induced using lysosomotropic reagents, depletion of lysosomal enzymes, or more toxic species of αSyn fibrils also exacerbated the propagation of αSyn aggregation, and impaired lysophagy and lysosomal membrane damage synergistically enhanced propagation. These results indicate that lysophagy prevents exogenous αSyn aggregates from escaping the endosomal-lysosomal system and transmitting aggregation to endogenous cytosolic αSyn via ruptured lysosomal vesicles. Our findings suggest that the progression and severity of synucleinopathies are associated with damage to lysosomal membranes and impaired lysophagy.
Collapse
Affiliation(s)
- Keita Kakuda
- Department of Neurology, Osaka University, Graduate School of Medicine, Suita, Osaka565-0871, Japan
| | - Kensuke Ikenaka
- Department of Neurology, Osaka University, Graduate School of Medicine, Suita, Osaka565-0871, Japan
| | - Akiko Kuma
- Department of Genetics, Osaka University, Graduate School of Medicine, Suita, Osaka565-0871, Japan
| | - Junko Doi
- Department of Neurology, Osaka University, Graduate School of Medicine, Suita, Osaka565-0871, Japan
| | - César Aguirre
- Department of Neurology, Osaka University, Graduate School of Medicine, Suita, Osaka565-0871, Japan
| | - Nan Wang
- Department of Neurology, Osaka University, Graduate School of Medicine, Suita, Osaka565-0871, Japan
| | - Takahiro Ajiki
- Department of Neurology, Osaka University, Graduate School of Medicine, Suita, Osaka565-0871, Japan
| | - Chi-Jing Choong
- Department of Neurology, Osaka University, Graduate School of Medicine, Suita, Osaka565-0871, Japan
| | - Yasuyoshi Kimura
- Department of Neurology, Osaka University, Graduate School of Medicine, Suita, Osaka565-0871, Japan
| | - Shaymaa Mohamed Mohamed Badawy
- Department of Neurology, Osaka University, Graduate School of Medicine, Suita, Osaka565-0871, Japan
- Department of Agricultural Biochemistry, Faculty of Agriculture, Zagazig University, Zagazig44519, Egypt
| | - Takayuki Shima
- Department of Genetics, Osaka University, Graduate School of Medicine, Suita, Osaka565-0871, Japan
| | - Shuhei Nakamura
- Department of Biochemistry, Nara Medical University, Kashihara, Nara634-8521, Japan
| | - Kousuke Baba
- Department of Neurology, Osaka University, Graduate School of Medicine, Suita, Osaka565-0871, Japan
- Department of Neurotherapeutics, Osaka University, Graduate School of Medicine, Suita, Osaka565-0871, Japan
| | - Seiichi Nagano
- Department of Neurology, Osaka University, Graduate School of Medicine, Suita, Osaka565-0871, Japan
- Department of Neurotherapeutics, Osaka University, Graduate School of Medicine, Suita, Osaka565-0871, Japan
| | - Yoshitaka Nagai
- Department of Neurology, Kindai University, Faculty of Medicine, Osaka-sayama, Osaka589-8511, Japan
| | - Tamotsu Yoshimori
- Department of Genetics, Osaka University, Graduate School of Medicine, Suita, Osaka565-0871, Japan
| | - Hideki Mochizuki
- Department of Neurology, Osaka University, Graduate School of Medicine, Suita, Osaka565-0871, Japan
| |
Collapse
|
5
|
Fukusumi H, Togo K, Beck G, Shofuda T, Kanematsu D, Yamamoto A, Sumida M, Baba K, Mochizuki H, Kanemura Y. Human induced pluripotent stem cell line (ONHi001-A) generated from a patient with infantile neuroaxonal dystrophy having PLA2G6 c.517C > T (p.Q173X) and c.1634A > G (p.K545R) compound heterozygous mutations. Stem Cell Res 2023; 69:103122. [PMID: 37209469 DOI: 10.1016/j.scr.2023.103122] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/13/2023] [Revised: 04/13/2023] [Accepted: 05/09/2023] [Indexed: 05/22/2023] Open
Abstract
Infantile neuroaxonal dystrophy (INAD) is a rare neurodegenerative disease caused mainly by homozygous or compound heterozygous mutations in the PLA2G6 gene. We generated a human induced pluripotent stem cell (hiPSC) line (ONHi001-A) using fibroblasts derived from a patient with INAD. The patient exhibited c.517C > T (p.Q173X) and c.1634A > G (p.K545R) compound heterozygous mutations in the PLA2G6 gene. This hiPSC line may be useful for studying the pathogenic mechanism underlying INAD.
Collapse
Affiliation(s)
- Hayato Fukusumi
- Division of Stem Cell Research, Department of Biomedical Research and Innovation, Institute for Clinical Research, National Hospital Organization Osaka National Hospital, Japan
| | - Kazuyuki Togo
- Department of Neurology, Graduate School of Medicine, Osaka University, Japan
| | - Goichi Beck
- Department of Neurology, Graduate School of Medicine, Osaka University, Japan
| | - Tomoko Shofuda
- Division of Stem Cell Research, Department of Biomedical Research and Innovation, Institute for Clinical Research, National Hospital Organization Osaka National Hospital, Japan
| | - Daisuke Kanematsu
- Division of Regenerative Medicine, Department of Biomedical Research and Innovation, Institute for Clinical Research, National Hospital Organization Osaka National Hospital, Japan
| | - Atsuyo Yamamoto
- Division of Regenerative Medicine, Department of Biomedical Research and Innovation, Institute for Clinical Research, National Hospital Organization Osaka National Hospital, Japan
| | - Miho Sumida
- Division of Regenerative Medicine, Department of Biomedical Research and Innovation, Institute for Clinical Research, National Hospital Organization Osaka National Hospital, Japan
| | - Kousuke Baba
- Department of Neurology, Graduate School of Medicine, Osaka University, Japan
| | - Hideki Mochizuki
- Department of Neurology, Graduate School of Medicine, Osaka University, Japan
| | - Yonehiro Kanemura
- Division of Regenerative Medicine, Department of Biomedical Research and Innovation, Institute for Clinical Research, National Hospital Organization Osaka National Hospital, Japan; Department of Neurosurgery, National Hospital Organization Osaka National Hospital, Japan
| |
Collapse
|
6
|
Choong CJ, Aguirre C, Kakuda K, Beck G, Nakanishi H, Kimura Y, Shimma S, Nabekura K, Hideshima M, Doi J, Yamaguchi K, Nakajima K, Wadayama T, Hayakawa H, Baba K, Ogawa K, Takeuchi T, Badawy SMM, Murayama S, Nagano S, Goto Y, Miyanoiri Y, Nagai Y, Mochizuki H, Ikenaka K. Phosphatidylinositol-3,4,5-trisphosphate interacts with alpha-synuclein and initiates its aggregation and formation of Parkinson's disease-related fibril polymorphism. Acta Neuropathol 2023; 145:573-595. [PMID: 36939875 PMCID: PMC10119223 DOI: 10.1007/s00401-023-02555-3] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2022] [Revised: 02/28/2023] [Accepted: 03/01/2023] [Indexed: 03/21/2023]
Abstract
Lipid interaction with α-synuclein (αSyn) has been long implicated in the pathogenesis of Parkinson's disease (PD). However, it has not been fully determined which lipids are involved in the initiation of αSyn aggregation in PD. Here exploiting genetic understanding associating the loss-of-function mutation in Synaptojanin 1 (SYNJ1), a phosphoinositide phosphatase, with familial PD and analysis of postmortem PD brains, we identified a novel lipid molecule involved in the toxic conversion of αSyn and its relation to PD. We first established a SYNJ1 knockout cell model and found SYNJ1 depletion increases the accumulation of pathological αSyn. Lipidomic analysis revealed SYNJ1 depletion elevates the level of its substrate phosphatidylinositol-3,4,5-trisphosphate (PIP3). We then employed Caenorhabditis elegans model to examine the effect of SYNJ1 defect on the neurotoxicity of αSyn. Mutations in SYNJ1 accelerated the accumulation of αSyn aggregation and induced locomotory defects in the nematodes. These results indicate that functional loss of SYNJ1 promotes the pathological aggregation of αSyn via the dysregulation of its substrate PIP3, leading to the aggravation of αSyn-mediated neurodegeneration. Treatment of cultured cell line and primary neurons with PIP3 itself or with PIP3 phosphatase inhibitor resulted in intracellular formation of αSyn inclusions. Indeed, in vitro protein-lipid overlay assay validated that phosphoinositides, especially PIP3, strongly interact with αSyn. Furthermore, the aggregation assay revealed that PIP3 not only accelerates the fibrillation of αSyn, but also induces the formation of fibrils sharing conformational and biochemical characteristics similar to the fibrils amplified from the brains of PD patients. Notably, the immunohistochemical and lipidomic analyses on postmortem brain of patients with sporadic PD showed increased PIP3 level and its colocalization with αSyn. Taken together, PIP3 dysregulation promotes the pathological aggregation of αSyn and increases the risk of developing PD, and PIP3 represents a potent target for intervention in PD.
Collapse
Affiliation(s)
- Chi-Jing Choong
- Department of Neurology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan
| | - César Aguirre
- Department of Neurology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan
| | - Keita Kakuda
- Department of Neurology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan
| | - Goichi Beck
- Department of Neurology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan
| | | | - Yasuyoshi Kimura
- Department of Neurology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan
| | - Shuichi Shimma
- Department of Biotechnology, Graduate School of Engineering, Osaka University, 2-1 Yamadaoka, Suita, Osaka, 565-0871, Japan
| | - Kei Nabekura
- Department of Neurology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan
| | - Makoto Hideshima
- Department of Neurology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan
| | - Junko Doi
- Department of Neurology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan
| | - Keiichi Yamaguchi
- Global Center for Medical Engineering and Informatics, Osaka University, 2-1 Yamadaoka, Suita, Osaka, 565-0871, Japan
| | - Kichitaro Nakajima
- Global Center for Medical Engineering and Informatics, Osaka University, 2-1 Yamadaoka, Suita, Osaka, 565-0871, Japan
| | - Tomoya Wadayama
- Department of Neurology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan
| | - Hideki Hayakawa
- Department of Neurology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan
| | - Kousuke Baba
- Department of Neurology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan
| | - Kotaro Ogawa
- Department of Neurology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan
| | - Toshihide Takeuchi
- Department of Neurology, Kindai University, 3-4-1 Kowakae, Higashiosaka City, Osaka, 577-8502, Japan
| | - Shaymaa Mohamed Mohamed Badawy
- Department of Neurology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.,Department of Agricultural Biochemistry, Faculty of Agriculture, Zagazig University, Zagazig, Egypt
| | - Shigeo Murayama
- Brain Bank for Neurodevelopmental, Neurological and Psychiatric Disorders, United Graduate School of Child Development, Osaka University, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan
| | - Seiichi Nagano
- Department of Neurology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan
| | - Yuji Goto
- Global Center for Medical Engineering and Informatics, Osaka University, 2-1 Yamadaoka, Suita, Osaka, 565-0871, Japan
| | - Yohei Miyanoiri
- Institute for Protein Research, Osaka University, 3-2 Yamadaoka, Suita, Osaka, 565-0871, Japan
| | - Yoshitaka Nagai
- Department of Neurology, Kindai University, 3-4-1 Kowakae, Higashiosaka City, Osaka, 577-8502, Japan
| | - Hideki Mochizuki
- Department of Neurology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.
| | - Kensuke Ikenaka
- Department of Neurology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.
| |
Collapse
|
7
|
Baba K, Fukuda T, Furuta M, Tada S, Imai A, Asano Y, Sugie H, P Takahashi M, Mochizuki H. A Mild Clinical Phenotype with Myopathic and Hemolytic Forms of Phosphoglycerate Kinase Deficiency (PGK Osaka): A Case Report and Literature Review. Intern Med 2022; 61:3589-3594. [PMID: 35527021 PMCID: PMC9790788 DOI: 10.2169/internalmedicine.9221-21] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/07/2023] Open
Abstract
Phosphoglycerate kinase (PGK) deficiency is an X-linked disorder characterized by a combination of hemolytic anemia, myopathy, and brain involvement. We herein report a Japanese man who had several episodes of rhabdomyolysis but was training strenuously to be a professional boxer. Mild hemolytic anemia was noted. The enzymatic activity of PGK was significantly reduced, and a novel missense mutation, p.S62N, was identified in the PGK1 gene. A literature review revealed only one case with a mixed hemolytic and myopathic phenotype like ours. This mild phenotype indicates the complex pathophysiology of PGK deficiency and suggests the benefits of dietary control and exercise.
Collapse
Affiliation(s)
- Kousuke Baba
- Department of Neurology, Osaka University Graduate School of Medicine, Japan
| | - Tokiko Fukuda
- Department of Pediatrics, Hamamatsu University School of Medicine, Japan
| | - Mitsuru Furuta
- Department of Neurology, Osaka University Graduate School of Medicine, Japan
| | - Satoru Tada
- Department of Neurology, Osaka University Graduate School of Medicine, Japan
| | - Atsuko Imai
- Department of Cardiology, Osaka University Graduate School of Medicine, Japan
| | - Yoshihiro Asano
- Department of Cardiology, Osaka University Graduate School of Medicine, Japan
| | - Hideo Sugie
- Faculty of Health and Medical Sciences, Tokoha University, Japan
| | - Masanori P Takahashi
- Department of Neurology, Osaka University Graduate School of Medicine, Japan
- Department of Clinical Laboratory and Biomedical Sciences, Osaka University Graduate School of Medicine, Japan
| | - Hideki Mochizuki
- Department of Neurology, Osaka University Graduate School of Medicine, Japan
| |
Collapse
|
8
|
Hirohata T, Kitano T, Saeki C, Baba K, Yoshida F, Kurihara T, Harada K, Saito S, Mochizuki H, Shimodozono M. Quantitative behavioral evaluation of a non-human primate stroke model using a new monitoring system. Front Neurosci 2022; 16:964928. [PMID: 36117634 PMCID: PMC9475201 DOI: 10.3389/fnins.2022.964928] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2022] [Accepted: 08/12/2022] [Indexed: 11/13/2022] Open
Abstract
Background Recently, the common marmoset (Callithrix jacchus) has attracted significant interest as a non-human primate stroke model. Functional impairment in non-human primate stroke models should be evaluated quantitatively and successively after stroke, but conventional observational assessments of behavior cannot fully fit this purpose. In this paper, we report a behavioral analysis using MarmoDetector, a three-dimensional motion analysis, in an ischemic stroke model using photosensitive dye, along with an observational behavioral assessment and imaging examination. Methods Ischemic stroke was induced in the left hemisphere of three marmosets. Cerebral infarction was induced by intravenous injection of rose bengal and irradiation with green light. The following day, the success of the procedure was confirmed by magnetic resonance imaging (MRI). The distance traveled, speed, activity time, and jumps/climbs were observed for 28 days after stroke using MarmoDetector. We also assessed the marmosets’ specific movements and postural abnormalities using conventional neurological scores. Results Magnetic resonance imaging diffusion-weighted and T2-weighted images showed hyperintense signals, indicating cerebral infarction in all three marmosets. MarmoDetector data showed that the both indices immediately after stroke onset and gradually improved over weeks. Neurological scores were the worst immediately after stroke and did not recover to pre-infarction levels during the observation period (28 days). A significant correlation was observed between MarmoDetector data and conventional neurological scores. Conclusion In this study, we showed that MarmoDetector can quantitatively evaluate behavioral changes in the acute to subacute phases stroke models. This technique can be practical for research on the pathophysiology of ischemic stroke and for the development of new therapeutic methods.
Collapse
Affiliation(s)
- Toshikazu Hirohata
- Department of Rehabilitation and Physical Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan
| | - Takaya Kitano
- Department of Neurology, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Chizu Saeki
- Department of Neurology, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Kousuke Baba
- Department of Neurology, Osaka University Graduate School of Medicine, Osaka, Japan
- Academic Research Division, Department of Neurology, Faculty of Medicine, University of Toyama, Toyama, Japan
- *Correspondence: Kousuke Baba,
| | - Fumiaki Yoshida
- Department of Anatomy and Physiology, Faculty of Medicine, Saga University, Saga, Japan
- Fumiaki Yoshida,
| | - Takashi Kurihara
- Department of Pharmacology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan
- Takashi Kurihara,
| | - Katsuhiro Harada
- Department of Rehabilitation and Physical Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan
| | - Shigeyoshi Saito
- Division of Health Sciences, Department of Medical Physics and Engineering, Osaka University Graduate School of Medicine, Suita, Japan
| | - Hideki Mochizuki
- Department of Neurology, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Megumi Shimodozono
- Department of Rehabilitation and Physical Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan
| |
Collapse
|
9
|
Wadayama T, Shimizu M, Kimura I, Baba K, Beck G, Nagano S, Morita R, Nakagawa H, Shirano M, Goto T, Norose K, Hikosaka K, Murayama S, Mochizuki H. Erdheim-Chester Disease Involving the Central Nervous System with Latent Toxoplasmosis. Intern Med 2022; 61:2661-2666. [PMID: 35135916 PMCID: PMC9492489 DOI: 10.2169/internalmedicine.8564-21] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/23/2021] [Accepted: 12/02/2021] [Indexed: 12/25/2022] Open
Abstract
Erdheim-Chester disease (ECD) is a rare, non-Langerhans cell histiocytosis characterized by the infiltration of foamy histiocytes into multiple organs. We herein report a case of ECD with central nervous system (CNS) involvement in a 63-year-old man who also presented a positive result for Toxoplasma gondii nested polymerase chain reaction testing of cerebrospinal fluid. Since anti-Toxoplasma treatment proved completely ineffective, we presumed latent infection of the CNS with T. gondii. This case suggests the difficulty of distinguishing ECD with CNS involvement from toxoplasmic encephalitis and the possibility of a relationship between the pathogeneses of ECD and infection with T. gondii.
Collapse
Affiliation(s)
- Tomoya Wadayama
- Department of Neurology, Osaka University Graduate School of Medicine, Japan
| | - Mikito Shimizu
- Department of Neurology, Osaka University Graduate School of Medicine, Japan
| | - Ikko Kimura
- Graduate School of Frontier Biosciences, Osaka University, Japan
| | - Kousuke Baba
- Department of Neurology, Osaka University Graduate School of Medicine, Japan
| | - Goichi Beck
- Department of Neurology, Osaka University Graduate School of Medicine, Japan
| | - Seiichi Nagano
- Department of Neurology, Osaka University Graduate School of Medicine, Japan
| | - Ryo Morita
- Department of Infectious Diseases, Osaka City General Hospital, Japan
| | - Hidenori Nakagawa
- Department of Infectious Diseases, Osaka City General Hospital, Japan
| | - Michinori Shirano
- Department of Infectious Diseases, Osaka City General Hospital, Japan
| | - Tetsushi Goto
- Department of Infectious Diseases, Osaka City General Hospital, Japan
| | - Kazumi Norose
- Department of Infection and Host Defense, Graduate School of Medicine, Chiba University, Japan
| | - Kenji Hikosaka
- Department of Infection and Host Defense, Graduate School of Medicine, Chiba University, Japan
| | - Shigeo Murayama
- Department of Neurology, Osaka University Graduate School of Medicine, Japan
| | - Hideki Mochizuki
- Department of Neurology, Osaka University Graduate School of Medicine, Japan
| |
Collapse
|
10
|
John MT, Omara M, Su N, List T, Sekulic S, Häggman-Henrikson B, Visscher CM, Bekes K, Reissmann DR, Baba K, Schierz O, Theis-Mahon N, Fueki K, Stamm T, Bondemark L, Oghli I, van Wijk A, Larsson P. RECOMMENDATIONS FOR USE AND SCORING OF ORAL HEALTH IMPACT PROFILE VERSIONS. J Evid Based Dent Pract 2022; 22:101619. [PMID: 35219460 PMCID: PMC8886153 DOI: 10.1016/j.jebdp.2021.101619] [Citation(s) in RCA: 32] [Impact Index Per Article: 16.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2019] [Revised: 07/11/2021] [Accepted: 07/22/2021] [Indexed: 02/08/2023]
Abstract
BACKGROUND OHIP's original seven-domain structure does not fit empirical data, but a psychometrically sound and clinically more plausible structure with the four OHRQoL dimensions Oral Function, Orofacial Pain, Orofacial Appearance, and Psychosocial Impact has emerged. Consequently, use and scoring of available OHIP versions need to be revisited. AIM We assessed how well the overall construct OHRQoL and its four dimensions were measured with several OHIP versions (20, 19, 14, and 5 items) to derive recommendations which instruments should be used and how to score them. METHODS Data came from the "Dimensions of OHRQoL Project" and used the project's learning sample (5,173 prosthodontic patients and general population subjects with 49-item OHIP data). We computed correlations among OHIP versions' summary scores. Correlations between OHRQoL dimensions, on one hand, and OHIP versions' domain scores or OHIP-5's items, on the other hand, were also computed. OHIP use and scoring recommendations were derived for psychometrically solid but also practical OHRQoL assessment. RESULTS Summary scores of 5-, 14-, 19- and 49-item versions correlated highly (r = 0.91-0.98), suggesting similar OHRQoL construct measurement across versions. The OHRQoL dimensions Oral Function, Orofacial Pain, Orofacial Appearance, and Psychosocial Impact were best measured by the OHIP domain scores for Physical Disability, Physical Pain, Psychological Discomfort, and Handicap, respectively. CONCLUSION Recommendations were derived which OHIP should be preferably used and how OHIP versions should be scored to capture the overall construct and the dimensions of OHRQoL. Psychometrically solid and practical OHRQoL assessment in all settings across all oral health conditions can be achieved with the 5-item OHIP.
Collapse
Affiliation(s)
- MT John
- Department of Diagnostic and Biological Sciences, School of Dentistry, University of Minnesota, Minneapolis, USA,Division of Epidemiology & Community Health, School of Public Health, University of Minnesota, USA
| | - M Omara
- Section for Outcomes Research, Center for Medical Statistics, Informatics, and Intelligent Systems, Medical University of Vienna, Spitalgasse 23, 1090, Vienna, Austria,Ludwig Boltzmann Institute for Arthritis and Rehabilitation, Nußdorfer Strasse 64, 1090, Vienna, Austria
| | - N Su
- Department of Social Dentistry, Academic Centre for Dentistry Amsterdam (ACTA), University of Amsterdam & Vrije Universiteit Amsterdam, Amsterdam, the Netherlands
| | - T List
- Department of Orofacial Pain and Jaw Function, Faculty of Odontology, Malmö University, Sweden,Scandinavian Center for Orofacial Neurosciences (http://www.sconresearch.eu/),Department of Rehabilitation Medicine, Skåne University Hospital, Sweden
| | - S Sekulic
- Dental Division, Department for Prosthetic Dentistry, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
| | - B Häggman-Henrikson
- Department of Orofacial Pain and Jaw Function, Faculty of Odontology, Malmö University, Sweden,Scandinavian Center for Orofacial Neurosciences (http://www.sconresearch.eu/)
| | - CM Visscher
- Department of Orofacial Pain and Disfunction, Academic Center for Dentistry Amsterdam (ACTA), University of Amsterdam and VU University Amsterdam, Amsterdam, The Netherlands
| | - K Bekes
- Department of Pediatric Dentistry, University Clinic of Dentistry, Medical University of Vienna, Vienna, Austria
| | - DR Reissmann
- Department of Prosthetic Dentistry, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - K Baba
- Department of Prosthodontics, Showa University, Tokyo, Japan
| | - O Schierz
- Department of Prosthodontics and Materials Science, University of Leipzig, Germany
| | - N Theis-Mahon
- Health Sciences Libraries, University of Minnesota, Minneapolis, MN, USA
| | - K Fueki
- Removable Partial Prosthodontics, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Japan
| | - T Stamm
- Section for Outcomes Research, Center for Medical Statistics, Informatics, and Intelligent Systems, Medical University of Vienna, Spitalgasse 23, 1090, Vienna, Austria
| | - L Bondemark
- Department of Orthodontics, Faculty of Odontology, Malmö, Sweden
| | - I Oghli
- Department of Orofacial Pain and Jaw Function, Faculty of Odontology, Malmö University, Sweden,Scandinavian Center for Orofacial Neurosciences (http://www.sconresearch.eu/),Department of Oral Basic Sciences, Taibah University, Medina, Saudi Arabia
| | - A van Wijk
- Department of Social Dentistry, Academic Centre for Dentistry Amsterdam (ACTA), University of Amsterdam & Vrije Universiteit Amsterdam, Amsterdam, the Netherlands
| | - P Larsson
- Department of Orofacial Pain and Jaw Function, Faculty of Odontology, Malmö University, Sweden,Scandinavian Center for Orofacial Neurosciences (http://www.sconresearch.eu/),Centre for Oral Rehabilitation, Folktandvården Östergötland, Linköping, Sweden
| |
Collapse
|
11
|
Ikenaka K, Maeda Y, Hotta Y, Nagano S, Yamada S, Ito D, Torii R, Kakuda K, Tatebe H, Atsuta N, Aguirre C, Kimura Y, Baba K, Tokuda T, Katsuno M, Kimura K, Sobue G, Mochizuki H. Serum asymmetric dimethyl arginine level correlates with the progression and prognosis of amyotrophic lateral sclerosis. Eur J Neurol 2022; 29:1410-1416. [PMID: 35128793 PMCID: PMC9305138 DOI: 10.1111/ene.15254] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2021] [Accepted: 01/13/2022] [Indexed: 11/29/2022]
Abstract
Background and purpose: Methods Results Conclusion
Collapse
Affiliation(s)
- Kensuke Ikenaka
- Department of Neurology Osaka University Graduate School of Medicine Suita Japan
| | - Yasuhiro Maeda
- Center for Joint Research Facilities Support Fujita Health University Toyoake Japan
| | - Yuji Hotta
- Department of Hospital Pharmacy Nagoya City University Graduate School of Pharmaceutical Sciences Nagoya Japan
| | - Seiichi Nagano
- Department of Neurology Osaka University Graduate School of Medicine Suita Japan
| | - Shinichiro Yamada
- Department of Neurology Nagoya University Graduate School of Medicine Nagoya Japan
| | - Daisuke Ito
- Department of Neurology Nagoya University Graduate School of Medicine Nagoya Japan
| | - Ryota Torii
- Department of Neurology Nagoya University Graduate School of Medicine Nagoya Japan
| | - Keita Kakuda
- Department of Neurology Osaka University Graduate School of Medicine Suita Japan
| | - Harutsugu Tatebe
- T Brothers Corporation T & Chiba Japan
- National Institutes for Quantum and Radiological Science and Technology (QST) Chiba Japan
| | - Naoki Atsuta
- Department of Neurology Nagoya University Graduate School of Medicine Nagoya Japan
- Department of Neurology Aichi Medical University School of Medicine Nagakute Japan
| | - Cesar Aguirre
- Department of Neurology Osaka University Graduate School of Medicine Suita Japan
| | - Yasuyoshi Kimura
- Department of Neurology Osaka University Graduate School of Medicine Suita Japan
| | - Kousuke Baba
- Department of Neurology Osaka University Graduate School of Medicine Suita Japan
| | - Takahiko Tokuda
- T Brothers Corporation T & Chiba Japan
- National Institutes for Quantum and Radiological Science and Technology (QST) Chiba Japan
| | - Masahisa Katsuno
- Department of Neurology Nagoya University Graduate School of Medicine Nagoya Japan
- Department of Clinical Research Education Nagoya University Graduate School of Medicine Nagoya Japan
| | - Kazunori Kimura
- Department of Hospital Pharmacy Nagoya City University Graduate School of Pharmaceutical Sciences Nagoya Japan
| | - Gen Sobue
- Research Division of Dementia and Neurodegenerative Disease Nagoya University Graduate School of Medicine Nagoya Japan
- Aichi Medical University Nagakute Japan
| | - Hideki Mochizuki
- Department of Neurology Osaka University Graduate School of Medicine Suita Japan
| |
Collapse
|
12
|
Abdelhamid RF, Ogawa K, Beck G, Ikenaka K, Takeuchi E, Yasumizu Y, Jinno J, Kimura Y, Baba K, Nagai Y, Okada Y, Saito Y, Murayama S, Mochizuki H, Nagano S. piRNA/PIWI Protein Complex as a Potential Biomarker in Sporadic Amyotrophic Lateral Sclerosis. Mol Neurobiol 2022; 59:1693-1705. [PMID: 35015250 PMCID: PMC8882100 DOI: 10.1007/s12035-021-02686-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2021] [Accepted: 12/08/2021] [Indexed: 12/12/2022]
Abstract
The pathological hallmark of the majority of amyotrophic lateral sclerosis (ALS) cases is the mislocalization and aggregation of TAR DNA-binding protein 43 (TDP-43), an RNA-binding protein. Several studies have attributed disease processes of ALS to abnormal RNA metabolism. However, dysregulated biogenesis of RNA, especially non-coding RNA (ncRNA), is poorly understood. To resolve it, RNA-Seq, biochemical, and immunohistochemical analyses were performed on the pyramidal tract of the medulla oblongata of sporadic ALS (sALS) and control postmortem brain samples. Here, we report perturbation of ncRNA biogenesis in PIWI-interacting RNA (piRNA) in several sALS brain samples associated with TDP-43 pathology. In addition, we confirmed the dysregulation of two PIWI homologs, PIWI-like-mediated gene silencing 1 (PIWIL1) and PIWIL4, which bind to piRNAs to regulate their expression. PIWIL1 was mislocalized and co-localized with TDP-43 in motor neurons of sporadic ALS lumbar cords. Our results imply that dysregulation of piRNA, PIWIL1, and PIWIL4 is linked to pathogenesis of ALS. Based on these results, piRNAs and PIWI proteins are potential diagnostic biomarkers and therapeutic targets of ALS.
Collapse
Affiliation(s)
- Rehab F Abdelhamid
- Department of Neurology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.,Department of Neurotherapeutics, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
| | - Kotaro Ogawa
- Department of Neurology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.,Department of Statistical Genetics, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
| | - Goichi Beck
- Department of Neurology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
| | - Kensuke Ikenaka
- Department of Neurology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
| | - Eriko Takeuchi
- Department of Neurology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
| | - Yoshiaki Yasumizu
- Department of Neurology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.,Department of Experimental Immunology, Osaka University Immunology Frontier Research Center, Suita, Osaka, Japan
| | - Jyunki Jinno
- Department of Neurology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
| | - Yasuyoshi Kimura
- Department of Neurology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
| | - Kousuke Baba
- Department of Neurology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
| | - Yoshitaka Nagai
- Department of Neurotherapeutics, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.,Department of Neurology, Faculty of Medicine, Kindai University, Osakasayama, Osaka, Japan
| | - Yukinori Okada
- Department of Statistical Genetics, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
| | - Yuko Saito
- Department of Neuropathology (Brain Bank for Aging Research), Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, Itabashi, Tokyo, Japan
| | - Shigeo Murayama
- Department of Neuropathology (Brain Bank for Aging Research), Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, Itabashi, Tokyo, Japan.,Brain Bank for Neurodevelopmental, Molecular Research Center for Children's Mental Development, Neurological and Psychiatric Disorders, Osaka University United Graduate School of Child Development, Suita, Osaka, Japan
| | - Hideki Mochizuki
- Department of Neurology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
| | - Seiichi Nagano
- Department of Neurology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan. .,Department of Neurotherapeutics, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
| |
Collapse
|
13
|
Hideshima M, Kimura Y, Aguirre C, Kakuda K, Takeuchi T, Choong CJ, Doi J, Nabekura K, Yamaguchi K, Nakajima K, Baba K, Nagano S, Goto Y, Nagai Y, Mochizuki H, Ikenaka K. Two-step screening method to identify α-synuclein aggregation inhibitors for Parkinson's disease. Sci Rep 2022; 12:351. [PMID: 35013421 PMCID: PMC8748996 DOI: 10.1038/s41598-021-04131-9] [Citation(s) in RCA: 11] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2021] [Accepted: 12/13/2021] [Indexed: 12/14/2022] Open
Abstract
Parkinson's disease is a neurodegenerative disease characterized by the formation of neuronal inclusions of α-synuclein in patient brains. As the disease progresses, toxic α-synuclein aggregates transmit throughout the nervous system. No effective disease-modifying therapy has been established, and preventing α-synuclein aggregation is thought to be one of the most promising approaches to ameliorate the disease. In this study, we performed a two-step screening using the thioflavin T assay and a cell-based assay to identify α-synuclein aggregation inhibitors. The first screening, thioflavin T assay, allowed the identification of 30 molecules, among a total of 1262 FDA-approved small compounds, which showed inhibitory effects on α-synuclein fibrilization. In the second screening, a cell-based aggregation assay, seven out of these 30 candidates were found to prevent α-synuclein aggregation without causing substantial toxicity. Of the seven final candidates, tannic acid was the most promising compound. The robustness of our screening method was validated by a primary neuronal cell model and a Caenorhabditis elegans model, which demonstrated the effect of tannic acid against α-synuclein aggregation. In conclusion, our two-step screening system is a powerful method for the identification of α-synuclein aggregation inhibitors, and tannic acid is a promising candidate as a disease-modifying drug for Parkinson's disease.
Collapse
Affiliation(s)
- Makoto Hideshima
- Department of Neurology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan
| | - Yasuyoshi Kimura
- Department of Neurology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan
| | - César Aguirre
- Department of Neurology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan
| | - Keita Kakuda
- Department of Neurology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan
| | - Toshihide Takeuchi
- Department of Neurology, Kindai University Faculty of Medicine, 377-2 Ohno-Higashi, Osaka-sayama, Osaka, 589-8511, Japan
- Department of Neurotherapeutics, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan
| | - Chi-Jing Choong
- Department of Neurology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan
| | - Junko Doi
- Department of Neurology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan
| | - Kei Nabekura
- Department of Neurology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan
| | - Keiichi Yamaguchi
- Global Center for Medical Engineering and Informatics, Osaka University, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan
- Institute for Protein Research, Osaka University, 3-2 Yamadaoka, Suita, Osaka, 565-0871, Japan
| | - Kichitaro Nakajima
- Global Center for Medical Engineering and Informatics, Osaka University, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan
| | - Kousuke Baba
- Department of Neurology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan
| | - Seiichi Nagano
- Department of Neurology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan
- Department of Neurotherapeutics, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan
| | - Yuji Goto
- Global Center for Medical Engineering and Informatics, Osaka University, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan
- Institute for Protein Research, Osaka University, 3-2 Yamadaoka, Suita, Osaka, 565-0871, Japan
| | - Yoshitaka Nagai
- Department of Neurology, Kindai University Faculty of Medicine, 377-2 Ohno-Higashi, Osaka-sayama, Osaka, 589-8511, Japan
- Department of Neurotherapeutics, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan
| | - Hideki Mochizuki
- Department of Neurology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.
| | - Kensuke Ikenaka
- Department of Neurology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.
| |
Collapse
|
14
|
Togo K, Fukusumi H, Shofuda T, Ohnishi H, Yamazaki H, Hayashi MK, Kawasaki N, Takei N, Nakazawa T, Saito Y, Baba K, Hashimoto H, Sekino Y, Shirao T, Mochizuki H, Kanemura Y. Postsynaptic structure formation of human iPS cell-derived neurons takes longer than presynaptic formation during neural differentiation in vitro. Mol Brain 2021; 14:149. [PMID: 34629097 PMCID: PMC8504131 DOI: 10.1186/s13041-021-00851-1] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2021] [Accepted: 09/04/2021] [Indexed: 11/10/2022] Open
Abstract
The generation of mature synaptic structures using neurons differentiated from human-induced pluripotent stem cells (hiPSC-neurons) is expected to be applied to physiological studies of synapses in human cells and to pathological studies of diseases that cause abnormal synaptic function. Although it has been reported that synapses themselves change from an immature to a mature state as neurons mature, there are few reports that clearly show when and how human stem cell-derived neurons change to mature synaptic structures. This study was designed to elucidate the synapse formation process of hiPSC-neurons. We propagated hiPSC-derived neural progenitor cells (hiPSC-NPCs) that expressed localized markers of the ventral hindbrain as neurospheres by dual SMAD inhibition and then differentiated them into hiPSC-neurons in vitro. After 49 days of in vitro differentiation, hiPSC-neurons significantly expressed pre- and postsynaptic markers at both the transcript and protein levels. However, the expression of postsynaptic markers was lower than in normal human or normal rat brain tissues, and immunostaining analysis showed that it was relatively modest and was lower than that of presynaptic markers and that its localization in synaptic structures was insufficient. Neurophysiological analysis using a microelectrode array also revealed that no synaptic activity was generated on hiPSC-neurons at 49 days of differentiation. Analysis of subtype markers by immunostaining revealed that most hiPSC-neurons expressed vesicular glutamate transporter 2 (VGLUT2). The presence or absence of NGF, which is required for the survival of cholinergic neurons, had no effect on their cell fractionation. These results suggest that during the synaptogenesis of hiPSC-neurons, the formation of presynaptic structures is not the only requirement for the formation of postsynaptic structures and that the mRNA expression of postsynaptic markers does not correlate with the formation of their mature structures. Technically, we also confirmed a certain level of robustness and reproducibility of our neuronal differentiation method in a multicenter setting, which will be helpful for future research. Synapse formation with mature postsynaptic structures will remain an interesting issue for stem cell-derived neurons, and the present method can be used to obtain early and stable quality neuronal cultures from hiPSC-NPCs.
Collapse
Affiliation(s)
- Kazuyuki Togo
- Department of Neurology, Graduate School of Medicine, Osaka University, Suita, Osaka, 565-0871, Japan.,Division of Stem Cell Research, Department of Biomedical Research and Innovation, Institute for Clinical Research, National Hospital Organization Osaka National Hospital, Osaka, Osaka, 540-0006, Japan
| | - Hayato Fukusumi
- Division of Stem Cell Research, Department of Biomedical Research and Innovation, Institute for Clinical Research, National Hospital Organization Osaka National Hospital, Osaka, Osaka, 540-0006, Japan
| | - Tomoko Shofuda
- Division of Stem Cell Research, Department of Biomedical Research and Innovation, Institute for Clinical Research, National Hospital Organization Osaka National Hospital, Osaka, Osaka, 540-0006, Japan
| | - Hiroshi Ohnishi
- Department of Laboratory Sciences, Gunma University Graduate School of Health Sciences, Maebashi, Gunma, 371-8514, Japan
| | - Hiroyuki Yamazaki
- Department of Neurobiology and Behavior, Gunma University Graduate School of Medicine, Maebashi, Gunma, 371-8511, Japan.,Faculty of Social Welfare, Gunma University of Health and Welfare, Maebashi, Gunma, 371-0823, Japan
| | - Mariko Kato Hayashi
- School of Medicine, International University of Health and Welfare, Narita, Chiba, 286-8686, Japan.,Department of Food Science and Nutrition, Faculty of Food and Health Sciences, Showa Women's University, Setagaya-ku, Tokyo, 154-8533, Japan
| | - Nana Kawasaki
- Laboratory of Biopharmaceutical and Regenerative Sciences, Graduate School of Medical Life Science, Yokohama City University, Yokohama, Kanagawa, 230-0045, Japan
| | - Nobuyuki Takei
- Department of Brain Tumor Biology, Brain Research Institute, Niigata University, Niigata, Niigata, 951-8585, Japan
| | - Takanobu Nakazawa
- Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka, 565-0871, Japan.,Department of Bioscience, Faculty of Life Sciences, Tokyo University of Agriculture, Setagaya-ku, Tokyo, 156-8502, Japan
| | - Yumiko Saito
- Graduate School of Integrated Sciences for Life, Hiroshima University, Higashi-Hiroshima, Hiroshima, 739-8521, Japan
| | - Kousuke Baba
- Department of Neurology, Graduate School of Medicine, Osaka University, Suita, Osaka, 565-0871, Japan
| | - Hitoshi Hashimoto
- Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka, 565-0871, Japan.,Molecular Research Center for Children's Mental Development, United Graduate School of Child Development, Osaka University, Suita, Osaka, 565-0871, Japan.,Division of Bioscience, Institute for Datability Science, Osaka University, Suita, Osaka, 565-0871, Japan.,Open and Transdisciplinary Research Initiatives, Osaka University, Suita, Osaka, 565-0871, Japan.,Department of Molecular Pharmaceutical Sciences, Graduate School of Medicine, Osaka University, Suita, Osaka, 565-0871, Japan
| | - Yuko Sekino
- Endowed Laboratory of Human Cell-Based Drug Discovery, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Bunkyo-ku, Tokyo, 113-0033, Japan
| | - Tomoaki Shirao
- Department of Neurobiology and Behavior, Gunma University Graduate School of Medicine, Maebashi, Gunma, 371-8511, Japan
| | - Hideki Mochizuki
- Department of Neurology, Graduate School of Medicine, Osaka University, Suita, Osaka, 565-0871, Japan
| | - Yonehiro Kanemura
- Division of Regenerative Medicine, Department of Biomedical Research and Innovation, Institute for Clinical Research, National Hospital Organization Osaka National Hospital, 2-1-14 Hoenzaka, Chuo-ku, Osaka, Osaka, 540-0006, Japan. .,Department of Neurosurgery, National Hospital Organization Osaka National Hospital, Osaka, Osaka, 540-0006, Japan.
| |
Collapse
|
15
|
Beck G, Hirozawa D, Honma K, Baba K, Sumi H, Morii E, Murayama S, Mochizuki H. Adult-Onset Biotinidase Deficiency Induces Acutely Progressing Leukoencephalopathy. Neurol Clin Pract 2021; 11:e383-e386. [PMID: 34484923 DOI: 10.1212/cpj.0000000000000862] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2019] [Accepted: 03/11/2020] [Indexed: 11/15/2022]
Affiliation(s)
- Goichi Beck
- Department of Neurology (GB, DH, KB, HS, SM, HM), Osaka University Graduate School of Medicine; Department of Pathology (KH, EM), Osaka University Graduate School of Medicine; and Department of Neurology and Neuropathology (the Brain Bank for Aging Research) (SM), Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology
| | - Daisuke Hirozawa
- Department of Neurology (GB, DH, KB, HS, SM, HM), Osaka University Graduate School of Medicine; Department of Pathology (KH, EM), Osaka University Graduate School of Medicine; and Department of Neurology and Neuropathology (the Brain Bank for Aging Research) (SM), Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology
| | - Keiichiro Honma
- Department of Neurology (GB, DH, KB, HS, SM, HM), Osaka University Graduate School of Medicine; Department of Pathology (KH, EM), Osaka University Graduate School of Medicine; and Department of Neurology and Neuropathology (the Brain Bank for Aging Research) (SM), Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology
| | - Kousuke Baba
- Department of Neurology (GB, DH, KB, HS, SM, HM), Osaka University Graduate School of Medicine; Department of Pathology (KH, EM), Osaka University Graduate School of Medicine; and Department of Neurology and Neuropathology (the Brain Bank for Aging Research) (SM), Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology
| | - Hisae Sumi
- Department of Neurology (GB, DH, KB, HS, SM, HM), Osaka University Graduate School of Medicine; Department of Pathology (KH, EM), Osaka University Graduate School of Medicine; and Department of Neurology and Neuropathology (the Brain Bank for Aging Research) (SM), Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology
| | - Eiichi Morii
- Department of Neurology (GB, DH, KB, HS, SM, HM), Osaka University Graduate School of Medicine; Department of Pathology (KH, EM), Osaka University Graduate School of Medicine; and Department of Neurology and Neuropathology (the Brain Bank for Aging Research) (SM), Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology
| | - Shigeo Murayama
- Department of Neurology (GB, DH, KB, HS, SM, HM), Osaka University Graduate School of Medicine; Department of Pathology (KH, EM), Osaka University Graduate School of Medicine; and Department of Neurology and Neuropathology (the Brain Bank for Aging Research) (SM), Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology
| | - Hideki Mochizuki
- Department of Neurology (GB, DH, KB, HS, SM, HM), Osaka University Graduate School of Medicine; Department of Pathology (KH, EM), Osaka University Graduate School of Medicine; and Department of Neurology and Neuropathology (the Brain Bank for Aging Research) (SM), Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology
| |
Collapse
|
16
|
Iizumi T, Okumura T, Maruo K, Baba K, Murakami M, Shimizu S, Saito T, Nakajima M, Makishima H, Numajiri H, Mizumoto M, Nakai K, Sakurai H. 943P Long-term outcome of the oldest-old patients (85 years or older) underwent proton beam therapy for hepatocellular carcinoma. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.163] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
17
|
Fukusumi H, Togo K, Sumida M, Nakamori M, Obika S, Baba K, Shofuda T, Ito D, Okano H, Mochizuki H, Kanemura Y. Alpha-synuclein dynamics in induced pluripotent stem cell-derived dopaminergic neurons from a Parkinson's disease patient (PARK4) with SNCA triplication. FEBS Open Bio 2021; 11:354-366. [PMID: 33301617 PMCID: PMC7876504 DOI: 10.1002/2211-5463.13060] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2020] [Revised: 11/06/2020] [Accepted: 12/08/2020] [Indexed: 12/11/2022] Open
Abstract
Parkinson's disease (PD) is a neurodegenerative disorder caused by the selective loss of dopaminergic (DA) neurons in the substantia nigra pars compacta (SNc). Lewy bodies (LBs), another histological hallmark of PD, are observed in patients with familial or sporadic PD. The therapeutic potential of reducing the accumulation of α‐synuclein, a major LB component, has been investigated, but it remains unknown whether the formation of LBs results in the loss of DA neurons. PARK4 patients exhibit multiplication of the α‐synuclein gene (SNCA) without any pathological mutations, but their symptoms develop relatively early. Therefore, study of PARK4 might help elucidate the mechanism of α‐synuclein aggregation. In this study, we investigated the dynamics of α‐synuclein during the early stage of immature DA neurons, which were differentiated from human‐induced pluripotent stem cells (hiPSCs) derived from either a PARK4 patient with SNCA triplication or a healthy donor. We observed increased α‐synuclein accumulation in PARK4 hiPSC‐derived DA neurons relative to those derived from healthy donor hiPSCs. Interestingly, α‐synuclein accumulation disappeared over time in the PARK4 patient‐derived DA neurons. Moreover, an SNCA‐specific antisense oligonucleotide could reduce α‐synuclein levels during the accumulation stage. These observations may help reveal the mechanisms that regulate α‐synuclein levels, which may consequently be useful in the development of new therapies for patients with sporadic or familial PD.
Collapse
Affiliation(s)
- Hayato Fukusumi
- Division of Stem Cell Research, Department of Biomedical Research and Innovation, Institute for Clinical Research, National Hospital Organization Osaka National Hospital, Japan
| | - Kazuyuki Togo
- Department of Neurology, Graduate School of Medicine, Osaka University, Japan
| | - Miho Sumida
- Division of Regenerative Medicine, Department of Biomedical Research and Innovation, Institute for Clinical Research, National Hospital Organization Osaka National Hospital, Japan
| | - Masayuki Nakamori
- Department of Neurology, Graduate School of Medicine, Osaka University, Japan
| | - Satoshi Obika
- Graduate School of Pharmaceutical Sciences, Osaka University, Japan
| | - Kousuke Baba
- Department of Neurology, Graduate School of Medicine, Osaka University, Japan
| | - Tomoko Shofuda
- Division of Stem Cell Research, Department of Biomedical Research and Innovation, Institute for Clinical Research, National Hospital Organization Osaka National Hospital, Japan
| | - Daisuke Ito
- Department of Neurology, Keio University School of Medicine, Tokyo, Japan
| | - Hideyuki Okano
- Department of Physiology, Keio University School of Medicine, Tokyo, Japan
| | - Hideki Mochizuki
- Department of Neurology, Graduate School of Medicine, Osaka University, Japan
| | - Yonehiro Kanemura
- Division of Regenerative Medicine, Department of Biomedical Research and Innovation, Institute for Clinical Research, National Hospital Organization Osaka National Hospital, Japan.,Department of Neurosurgery, National Hospital Organization Osaka National Hospital, Japan
| |
Collapse
|
18
|
Abstract
In addition to muscle nicotinic acetylcholine receptor (AChR) and muscle-specific kinase (MuSK), low-density lipoprotein receptor (Lrp4) has recently been discovered to be a novel target antigen among patients with seronegative myasthenia gravis (MG). We herein report the findings of a 62-year-old patient who showed positivity for anti-MuSK, anti-Lrp4, and anti-titin antibodies. The patient developed MG crisis following a 10-year history of intermittent double vision with ptosis, and a 7-year history of dropped head. Our detailed clinical, laboratory, and therapeutic descriptions highlight its unique characteristics of anti-MuSK-antibody positive MG accompanied by anti-Lrp4 and anti-titin antibodies.
Collapse
Affiliation(s)
- Rika Yamashita
- Department of Neurology, Osaka University Hospital, Japan
| | - Mikito Shimizu
- Department of Neurology, Osaka University Hospital, Japan
| | - Kousuke Baba
- Department of Neurology, Osaka University Hospital, Japan
| | - Goichi Beck
- Department of Neurology, Osaka University Hospital, Japan
| | | | | | - Osamu Higuchi
- Department of Clinical Research, Nagasaki Kawatana Medical Center, Japan
| | | |
Collapse
|
19
|
Jiang S, Baba K, Okuno T, Kinoshita M, Choong CJ, Hayakawa H, Sakiyama H, Ikenaka K, Nagano S, Sasaki T, Shimamura M, Nagai Y, Hagihara K, Mochizuki H. Go-sha-jinki-Gan Alleviates Inflammation in Neurological Disorders via p38-TNF Signaling in the Central Nervous System. Neurotherapeutics 2021; 18:460-473. [PMID: 33083995 PMCID: PMC8116410 DOI: 10.1007/s13311-020-00948-w] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/07/2020] [Indexed: 01/14/2023] Open
Abstract
Go-sha-jinki-Gan (GJG) is a traditional Japanese herbal medicine. In clinical practice, GJG is effective against neuropathic pain and hypersensitivity induced by chemotherapy or diabetes. In our previous study using a chronic constriction injury mouse model, we showed that GJG inhibited microglia activation by suppressing the expression of tumor necrosis factor-α (TNF-α) and p38 mitogen-activated protein kinase (p38 MAPK) in the peripheral nervous system. To investigate whether GJG can suppress inflammation in the central nervous system (CNS) in the context of neurological disorders, we examined the effect of GJG on the activation of resident glial cells and on p38-TNF signaling in two mouse models of neurological disorders: the experimental autoimmune encephalomyelitis (EAE) model of multiple sclerosis and the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model of Parkinson's disease. GJG administration relieved the severity of clinical EAE symptoms and MPTP-induced inflammation by decreasing the number of microglia and the production of TNF-α in the spinal cord of EAE mice and the substantia nigra of MPTP-treated mice. Accordingly, GJG suppressed the phosphorylation of p38 in glial cells of these two mouse models. We conclude that GJG attenuates inflammation of the CNS by suppressing glial cell activation, followed by a decrease in the production of TNF-α via p38-TNF signaling.
Collapse
Affiliation(s)
- Shiying Jiang
- Department of Neurology, Graduate School of Medicine, Osaka University, Suita, Osaka, 565-0871, Japan
| | - Kousuke Baba
- Department of Neurology, Graduate School of Medicine, Osaka University, Suita, Osaka, 565-0871, Japan
| | - Tatsusada Okuno
- Department of Neurology, Graduate School of Medicine, Osaka University, Suita, Osaka, 565-0871, Japan
| | - Makoto Kinoshita
- Department of Neurology, Graduate School of Medicine, Osaka University, Suita, Osaka, 565-0871, Japan
| | - Chi-Jing Choong
- Department of Neurology, Graduate School of Medicine, Osaka University, Suita, Osaka, 565-0871, Japan
| | - Hideki Hayakawa
- Department of Neurology, Graduate School of Medicine, Osaka University, Suita, Osaka, 565-0871, Japan
| | - Hiroshi Sakiyama
- Department of Neurology, Graduate School of Medicine, Osaka University, Suita, Osaka, 565-0871, Japan
| | - Kensuke Ikenaka
- Department of Neurology, Graduate School of Medicine, Osaka University, Suita, Osaka, 565-0871, Japan
| | - Seiichi Nagano
- Department of Neurology, Graduate School of Medicine, Osaka University, Suita, Osaka, 565-0871, Japan
| | - Tsutomu Sasaki
- Department of Neurology, Graduate School of Medicine, Osaka University, Suita, Osaka, 565-0871, Japan
| | - Munehisa Shimamura
- Department of Neurology, Graduate School of Medicine, Osaka University, Suita, Osaka, 565-0871, Japan
- Department of Health Development and Medicine, Graduate School of Medicine, Osaka University, Suita, Osaka, 565-0871, Japan
| | - Yoshitaka Nagai
- Department of Neurology, Graduate School of Medicine, Osaka University, Suita, Osaka, 565-0871, Japan
- Department of Neurotherapeutics, Graduate School of Medicine, Osaka University, Suita, Osaka, 565-0871, Japan
| | - Keisuke Hagihara
- Department of Advanced Hybrid Medicine, Graduate School of Medicine, Osaka University, Suita, Osaka, 565-0871, Japan.
| | - Hideki Mochizuki
- Department of Neurology, Graduate School of Medicine, Osaka University, Suita, Osaka, 565-0871, Japan.
| |
Collapse
|
20
|
Choong CJ, Okuno T, Ikenaka K, Baba K, Hayakawa H, Koike M, Yokota M, Doi J, Kakuda K, Takeuchi T, Kuma A, Nakamura S, Nagai Y, Nagano S, Yoshimori T, Mochizuki H. Alternative mitochondrial quality control mediated by extracellular release. Autophagy 2020; 17:2962-2974. [PMID: 33218272 PMCID: PMC8525996 DOI: 10.1080/15548627.2020.1848130] [Citation(s) in RCA: 43] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Mitochondrial quality control, which is crucial for maintaining cellular homeostasis, has been considered to be achieved exclusively through mitophagy. Here we report an alternative mitochondrial quality control pathway mediated by extracellular mitochondria release. By performing time-lapse confocal imaging on a stable cell line with fluorescent-labeled mitochondria, we observed release of mitochondria from cells into the extracellular space. Correlative light-electron microscopy revealed that majority of the extracellular mitochondria are in free form and, on rare occasions, some are enclosed in membrane-surrounded vesicles. Rotenone- and carbonyl cyanide m-chlorophenylhydrazone-induced mitochondrial quality impairment promotes the extracellular release of depolarized mitochondria. Overexpression of PRKN (parkin RBR E3 ubiquitin protein ligase), which has a pivotal role in mitophagy regulation, suppresses the extracellular mitochondria release under basal and stress condition, whereas its knockdown exacerbates it. Correspondingly, overexpression of PRKN-independent mitophagy regulators, BNIP3 (BCL2 interacting protein 3) and BNIP3L/NIX (BCL2 interacting protein 3 like), suppress extracellular mitochondria release. Autophagy-deficient cell lines show elevated extracellular mitochondria release. These results imply that perturbation of mitophagy pathway prompts mitochondria expulsion. Presence of mitochondrial protein can also be detected in mouse sera. Sera of PRKN-deficient mice contain higher level of mitochondrial protein compared to that of wild-type mice. More importantly, fibroblasts and cerebrospinal fluid samples from Parkinson disease patients carrying loss-of-function PRKN mutations show increased extracellular mitochondria compared to control subjects, providing evidence in a clinical context. Taken together, our findings suggest that extracellular mitochondria release is a comparable yet distinct quality control pathway from conventional mitophagy. Abbreviations: ACTB: actin beta; ANXA5: annexin A5; ATP5F1A/ATP5A: ATP synthase F1 subunit alpha; ATG: autophagy related; BNIP3: BCL2 interacting protein 3; BNIP3L/NIX: BCL2 interacting protein 3 like; CCCP: carbonyl cyanide m-chlorophenylhydrazone; CM: conditioned media; CSF: cerebrospinal fluid; DMSO: dimethyl sulfoxide; EM: electron microscopy; HSPD1/Hsp60: heat shock protein family D (Hsp60) member 1; KD: knockdown; KO: knockout; MAP1LC3A/LC3: microtubule associated protein 1 light chain 3 alpha; MT-CO1: mitochondrially encoded cytochrome c oxidase I; NDUFB8: NADH:ubiquinone oxidoreductase subunit B8; OE: overexpression; OPA1: OPA1 mitochondrial dynamin like GTPase; OXPHOS: oxidative phosphorylation; PBS: phosphate-buffered saline; PB: phosphate buffer; PD: Parkinson disease; PINK1: PTEN induced kinase 1; PRKN: parkin RBR E3 ubiquitin protein ligase; RB1CC1/FIP200: RB1 inducible coiled-coil 1; SDHB: succinate dehydrogenase complex iron sulfur subunit B; TOMM20: translocase of outer mitochondrial membrane 20; TOMM40: translocase of outer mitochondrial membrane 40; UQCRC2: ubiquinol-cytochrome c reductase core protein 2; WT: wild-type
Collapse
Affiliation(s)
- Chi-Jing Choong
- Department of Neurology, Osaka University Graduate School of Medicine, Suita, Japan
| | - Tatsusada Okuno
- Department of Neurology, Osaka University Graduate School of Medicine, Suita, Japan
| | - Kensuke Ikenaka
- Department of Neurology, Osaka University Graduate School of Medicine, Suita, Japan
| | - Kousuke Baba
- Department of Neurology, Osaka University Graduate School of Medicine, Suita, Japan
| | - Hideki Hayakawa
- Department of Neurology, Osaka University Graduate School of Medicine, Suita, Japan
| | - Masato Koike
- Department of Cell Biology and Neuroscience, Juntendo University Graduate School of Medicine, Tokyo, Japan
| | - Mutsumi Yokota
- Department of Cell Biology and Neuroscience, Juntendo University Graduate School of Medicine, Tokyo, Japan
| | - Junko Doi
- Department of Neurology, Osaka University Graduate School of Medicine, Suita, Japan
| | - Keita Kakuda
- Department of Neurology, Osaka University Graduate School of Medicine, Suita, Japan
| | - Toshihide Takeuchi
- Department of Neurotherapeutics, Osaka University Graduate School of Medicine, Suita, Japan
| | - Akiko Kuma
- Department of Genetics, Osaka University Graduate School of Medicine, Suita, Japan
| | - Shuhei Nakamura
- Department of Genetics, Osaka University Graduate School of Medicine, Suita, Japan
| | - Yoshitaka Nagai
- Department of Neurotherapeutics, Osaka University Graduate School of Medicine, Suita, Japan
| | - Seiichi Nagano
- Department of Neurology, Osaka University Graduate School of Medicine, Suita, Japan
| | - Tamotsu Yoshimori
- Department of Genetics, Osaka University Graduate School of Medicine, Suita, Japan
| | - Hideki Mochizuki
- Department of Neurology, Osaka University Graduate School of Medicine, Suita, Japan
| |
Collapse
|
21
|
Murofushi K, Tomita T, Ishida T, Baba K, Numajiri H, Mizumoto M, Ohnishi K, Nakai K, Ishikawa H, Okumura T, Sakurai H. The Incidence of Venous Thromboembolism Induced by Prolonged Bed Rest during Interstitial Brachytherapy for Gynecological Cancer. Int J Radiat Oncol Biol Phys 2020. [DOI: 10.1016/j.ijrobp.2020.07.1530] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
22
|
Hirai K, Baba K, Ohtsuki S, Oh H. Cardiosphere-derived exosomal microRNAs for cardiac repair in pediatric dilated cardiomyopathy: preclinical and safety lead-in phase 1 clinical studies. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.3608] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
Stem cell therapies have been shown to improve cardiac function; however, therapeutic potential of cardiosphere-derived cells (CDCs) in dilated cardiomyopathy (DCM) and the underlying mechanisms of paracrine effectors include CDC-secreted exosomes (CDCex) mediating cardiac repair remain unknown. Purpose- We aimed to evaluate the safety and therapeutic efficacy of CDCs in swine model of DCM and translate the preclinical results into children with DCM.
Methods
As a preclinical study, female Yorkshire pigs (n=15) were treated by intracoronary administration of microspheres (1.0×104 particles) to develop diffuse cardiac dysfunction and animals were randomly assigned to receive placebo or 9.0×106 CDC injection pretreated by DMSO or exosome inhibitor (EI; GW4869). CDCex-derived microRNAs (miRs) profile was assessed and ventricular ejection fraction (EF) was evaluated before and 1 month after cell infusion. In safety lead-in clinical trial, 5 patients with DCM (<18 years) with reduced EF (<40%) were prospectively enrolled to receive CDC infusion. The primary endpoint was to assess safety, and the secondary outcome measure was change in cardiac function over 12 months.
Results
Compared with placebo control, DMSO-treated CDC infusion resulted in improved cardiac function with decrease in myocardial fibrosis (18.2±4.1% versus; 9.5±3.6%; P<0.001) and enhanced cardiomyocyte cycling (Ki67: 27.2±3.6/106 myocytes versus 43.9±6.0/106 myocytes; P=0.002) and neovascularization (von Willebrand factor: 644.8±84.3/mm2 versus 820.7±159.7/mm2; P=0.01) at 1 month. miR expression analysis showed that CDCex were highly enriched with miR-126, miR-132, miR-146a, miR-181b, miR-210, and miR-451. Inhibition of CDCex-derived miRs production by EI pretreatment did not affect CDC viability but rendered CDC ineffective in functional improvement (ΔEF: +5.4%±2.0% versus −1.0%±2.1%; P=0.002). One-year follow-up of clinical trial was completed in 5 patients with favorable profile and preliminary efficacy outcomes. Echocardiographic measurements revealed that CDC infusion increased EF from baseline to 12 months of follow up (28.5±10.7% versus 33.0±11.1%; P=0.038) in accordance with reduced native T1 mapping (1041.6±60.4 ms versus 984.8±39.3 ms; P=0.025). CDCex-derived miRs profiles from patients demonstrated that several miRs were exclusively enriched in CDCs but human cardiac fibroblasts included miR-126, miR-132, miR-146a, miR-181b, and miR-210. Notably, miR-146a expression levels were positively correlated with the reduction in myocardial fibrosis 12 months after CDC infusion (Δnative T1: r=0.896, P=0.040).
Conclusions
Intracoronary delivery of CDCs is safe and improves cardiac function through CDCex-derived miRs secretion in swine model of DCM. The safety lead-in results in patients warrant further assessment of clinical benefits and highlight miR-146a as a major paracrine mediator of CDC's antifibrotic function for clinical therapeutics.
Funding Acknowledgement
Type of funding source: Public grant(s) – National budget only. Main funding source(s): Research Project for Practical Application of Regenerative Medicine (16bk0104052h0001, 17bk0104052h0002, 18bk0104052h0003) by the Japan Agency for Medical Research and Development
Collapse
Affiliation(s)
- K Hirai
- Okayama University, Pediatrics, Okayama, Japan
| | - K Baba
- Okayama University, Pediatrics, Okayama, Japan
| | - S Ohtsuki
- Okayama University, Pediatrics, Okayama, Japan
| | - H Oh
- Okayama University Hospital, Regenerative Medicine, Center for Innovative Clinical Medicine, Okayama, Japan
| |
Collapse
|
23
|
Hayano E, Shimizu M, Baba K, Shimamura M, Yoshida T, Mochizuki H. [A case of Alexander disease presented with dystonia of lower limb and decreased dopaminergic uptake in dopamine transporter scintigraphy]. Rinsho Shinkeigaku 2020; 60:712-715. [PMID: 32893243 DOI: 10.5692/clinicalneurol.cn-001445] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
A 50-year-old woman developed gait disturbances and dysarthria since the past 2 years. She also presented with dystonia and hypokinesia of her left lower limb, and orthostatic hypotension. The dopamine transporter SPECT with 123I ioflupane showed abnormal scans in bilateral striatum. Cerebral MRI revealed atrophy and signal changes in the medulla and spinal cord, from which Alexander disease (AxD) was suspected. Consequently, we checked the Glial fibrillary acidic protein (GFAP) gene. The analysis of the gene detected a heterozygous c.219G>T mutation, which was the first mutation reported in Japan, and finally she was diagnosed with AxD. Dystonia is relatively rare in AxD patients, but this case demonstrated that AxD should be listed in the differential diagnosis of extrapyramidal syndromes with abnormalities of the medulla and spinal cord on MRI.
Collapse
Affiliation(s)
- Eri Hayano
- Department of Neurology, Osaka University
| | | | | | | | | | | |
Collapse
|
24
|
Baba K, Tanaka H, Fujita Y, Nakamura A, Kikuchi E, Kawai Y, Harada T, Watanabe N, Yokouchi H, Usui K, Saito R, Watanabe H, Masuda T, Fukuhara T, Kudo K, Honda R, Oizimi S, Maemondo M, Inoue A, Morikawa N. A randomized, phase II study comparing irinotecan versus amrubicin as maintenance therapy after first-line induction therapy for extensive disease small cell lung cancer (HOT1401/NJLCG1401). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz437.046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
25
|
Hayakawa H, Nakatani R, Ikenaka K, Aguirre C, Choong CJ, Tsuda H, Nagano S, Koike M, Ikeuchi T, Hasegawa M, Papa SM, Nagai Y, Mochizuki H, Baba K. Structurally distinct α-synuclein fibrils induce robust parkinsonian pathology. Mov Disord 2019; 35:256-267. [PMID: 31643109 DOI: 10.1002/mds.27887] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2019] [Revised: 07/24/2019] [Accepted: 08/26/2019] [Indexed: 12/16/2022] Open
Abstract
OBJECTIVE Alpha-synuclein (α-syn) is a major component of Lewy bodies, which are the pathological hallmark in Parkinson's disease, and its genetic mutations cause familial forms of Parkinson's disease. Patients with α-syn G51D mutation exhibit severe clinical symptoms. However, in vitro studies showed low propensity for α-syn with the G51D mutation. We studied the mechanisms associated with severe neurotoxicity of α-syn G51D mutation using a murine model generated by G51D α-syn fibril injection into the brain. METHODS Structural analysis of wild-type and G51D α-syn-fibrils were performed using Fourier transform infrared spectroscopy. The ability of α-syn fibrils forming aggregates was first assessed in in vitro mammalian cells. An in vivo mouse model with an intranigral injection of α-syn fibrils was then used to evaluate the propagation pattern of α-syn and related cellular changes. RESULTS We found that G51D α-syn fibrils have higher β-sheet contents than wild-type α-syn fibrils. The addition of G51D α-syn fibrils to mammalian cells overexpressing α-syn resulted in the formation of phosphorylated α-syn inclusions at a higher rate. Similarly, an injection of G51D α-syn fibrils into the substantia nigra of a mouse brain induced more widespread phosphorylated α-syn pathology. Notably, the mice injected with G51D α-syn fibrils exhibited progressive nigral neuronal loss accompanied with mitochondrial abnormalities and motor impairment. CONCLUSION Our findings indicate that the structural difference of G51D α-syn fibrils plays an important role in the rapidly developed and more severe neurotoxicity of G51D mutation-linked Parkinson's disease. © 2019 International Parkinson and Movement Disorder Society.
Collapse
Affiliation(s)
- Hideki Hayakawa
- Department of Neurology, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Rie Nakatani
- Department of Neurology, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Kensuke Ikenaka
- Department of Neurology, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Cesar Aguirre
- Institute of Protein Research, Osaka University, Osaka, Japan
| | - Chi-Jing Choong
- Department of Neurology, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Hiroshi Tsuda
- Department of Neurology, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Seiichi Nagano
- Department of Neurology, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Masato Koike
- Department of Cell Biology and Neuroscience, Juntendo University Graduate School of Medicine, Tokyo, Japan
| | - Takeshi Ikeuchi
- Department of Molecular Genetics, Bioresource Science Branch, Center for Bioresources, Brain Research Institute, Niigata University, Niigata, Japan
| | - Masato Hasegawa
- Department of Neuropathology and Cell Biology, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan
| | - Stella M Papa
- Department of Neurology, Emory University School of Medicine, Atlanta, Georgia, USA
| | - Yoshitaka Nagai
- Department of Neurology, Osaka University Graduate School of Medicine, Osaka, Japan.,Department of Neurotherapeutics, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Hideki Mochizuki
- Department of Neurology, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Kousuke Baba
- Department of Neurology, Osaka University Graduate School of Medicine, Osaka, Japan
| |
Collapse
|
26
|
Nomura M, Nagatomo R, Inoue K, Doi K, Shimizu J, Baba K, Saito T, Matsumoto S, Muto M. Association of SCFA in gut microbiome and clinical response in solid cancer patients treated with andi-PD-1 antibody. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz253.074] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
27
|
Hirai K, Baba K, Goto T, Ousaka D, Oh H, Kasahara S, Ohtsuki S. P3651Outcomes of right ventricular outflow tract reconstruction in children: comparison between bovine jugular vein graft and expanded polytetrafluoroethylene graft. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz745.0508] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Various types of conduits are available for right ventricular outflow tract reconstruction (RVOTR). The bovine jugular vein graft (BJVG) and expanded polytetrafluoroethylene graft (ePTFEG) have been descrived as an alternative to the homograft for RVOTR. Purpose- This study summarized the results to evaluate the single-center operation of RVOTR using BJVG and ePTFEG.
Methods
The valve functions of 27 patients under 20 years old who underwent primary RVOTR with BJVG and 26 patients with ePTFEG at our university hospital between 2013 and 2018 were retrospectively investigated. The valve conditions were assessed using echocardiography and cardiac catheterization.
Results
The median age at the time of operation was 1.8 years old (range, 6 days to 7.8 years old) with BJVG and 2.2 years old (range, 8 months to 9.1 years old) with ePTFEG. The median follow-up time was 3.4 years (range, 2 months to 5.2 years) with BJVG and 2.1 years (range, 1 month to 5.1 years) with ePTFEG. The peak RVOT gradient of BJVG was lower than ePTFEG (10.6±7.7 mmHg versus 18.1±16.2 mmHg, P=0.035). There were no differences in branch pulmonary stenosis defined as peak gradient up to 36mmHg (40.7% versus 50.0%, P=0.50) and pulmonary regurgitation graded worse than moderate (18.5% versus 11.5%, P=0.48) with BJVG and ePTFEG, respectively. Aneurysmal dilatation of the conduit was seen 22.2% with BJVG but none of patients with ePTFEG (P=0.01). All of patients with aneurysmal dilated BJVG had branch pulmonary stenosis. There were no differences in catheter intervention for branch pulmonary stenosis (22.2% versus 30.8%, P=0.48) and conduit replacement (11.1% versus 7.7%, log rank P=0.67) with BJVG and ePTFEG, respectively. There were no deaths during the fllow-up period in both groups.
Conclusions
The outcomes of RVOTR with BJVG and ePTFEG were clinically satisfactory. Aneurysmal dilatation was seen with BJVG and branch pulmonary stenosis was the risk factor for aneurysmal dilatation.
Collapse
Affiliation(s)
- K Hirai
- Okayama University, Pediatrics, Okayama, Japan
| | - K Baba
- Okayama University, Pediatrics, Okayama, Japan
| | - T Goto
- Okayama University Hospital, Cardiovascular Surgery, Okayama, Japan
| | - D Ousaka
- Okayama University Hospital, Cardiovascular Surgery, Okayama, Japan
| | - H Oh
- Okayama University Hospital, Regenerative Medicine, Center for Innovative Clinical Medicine, Okayama, Japan
| | - S Kasahara
- Okayama University Hospital, Cardiovascular Surgery, Okayama, Japan
| | - S Ohtsuki
- Okayama University, Pediatrics, Okayama, Japan
| |
Collapse
|
28
|
Sakai R, Suzuki M, Ueyama M, Takeuchi T, Minakawa EN, Hayakawa H, Baba K, Mochizuki H, Nagai Y. E46K mutant α-synuclein is more degradation resistant and exhibits greater toxic effects than wild-type α-synuclein in Drosophila models of Parkinson's disease. PLoS One 2019; 14:e0218261. [PMID: 31242217 PMCID: PMC6594597 DOI: 10.1371/journal.pone.0218261] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2018] [Accepted: 05/29/2019] [Indexed: 12/11/2022] Open
Abstract
Parkinson’s disease (PD) is one of the most common neurodegenerative diseases, which is characterized by progressive motor dysfunction as well as non-motor symptoms. Pathological and genetic studies have demonstrated that α-synuclein (αSyn) plays key roles in the pathogenesis of PD. Although several missense mutations in the αSyn gene have been identified as causes of familial PD, the mechanisms underlying the variance in the clinical phenotypes of familial PD caused by different mutations remain elusive. Here, we established novel Drosophila models expressing either wild-type (WT) αSyn or one of five αSyn mutants (A30P, E46K, H50Q, G51D, and A53T) using site-specific transgenesis, which express transgenes at equivalent levels. Expression of either WT or mutant αSyn in the compound eyes by the GMR-GAL4 driver caused mild rough eye phenotypes with no obvious difference among the mutants. Upon pan-neuronal expression by the nSyb-GAL4 driver, these αSyn-expressing flies showed a progressive decline in locomotor function. Notably, we found that E46K, H50Q, G51D, and A53T αSyn-expressing flies showed earlier onset of locomotor dysfunction than WT αSyn-expressing flies, suggesting their enhanced toxic effects. Whereas mRNA levels of WT and mutant αSyn were almost equivalent, we found that protein expression levels of E46K αSyn were higher than those of WT αSyn. In vivo chase experiments using the drug-inducible GMR-GeneSwitch driver demonstrated that degradation of E46K αSyn protein was significantly slower than WT αSyn protein, indicating that the E46K αSyn mutant gains resistance to degradation in vivo. We therefore conclude that our novel site-specific transgenic fly models expressing either WT or mutant αSyn are useful to explore the mechanisms by which different αSyn mutants gain toxic functions in vivo.
Collapse
Affiliation(s)
- Ryusuke Sakai
- Department of Neurotherapeutics, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
- Department of Neurology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
| | - Mari Suzuki
- Department of Neurotherapeutics, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
- Diabetic Neuropathy Project, Department of Sensory and Motor Systems, Tokyo Metropolitan Institute of Medical Science, Setagaya, Tokyo, Japan
| | - Morio Ueyama
- Department of Neurotherapeutics, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
| | - Toshihide Takeuchi
- Department of Neurotherapeutics, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
| | - Eiko N. Minakawa
- Department of Degenerative Neurological Diseases, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan
| | - Hideki Hayakawa
- Department of Neurology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
| | - Kousuke Baba
- Department of Neurology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
| | - Hideki Mochizuki
- Department of Neurology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
| | - Yoshitaka Nagai
- Department of Neurotherapeutics, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
- Department of Neurology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
- * E-mail:
| |
Collapse
|
29
|
Abstract
Leading an academic discipline poses moral and ethical challenges, requiring a special set of capabilities. Leadership in a clinical academic discipline involves leading the transformation of education, research, leadership and patient care. Daily struggles within strategic, political and cultural milieu are the norm and effective leaders are able to navigate through these struggles and see opportunities for growth.
Collapse
Affiliation(s)
- S Koka
- Loma Linda University, Loma Linda, USA.
| | - K Baba
- Showa University, Tokyo, Japan
| | - C Ercoli
- Eastman Institute of Oral Health, University of Rochester, New York, USA
| | | | - X Jiang
- Shanghai Jiao Tong University, Shanghai, China
| |
Collapse
|
30
|
Uenaka T, Satake W, Cha PC, Hayakawa H, Baba K, Jiang S, Kobayashi K, Kanagawa M, Okada Y, Mochizuki H, Toda T. In silico drug screening by using genome-wide association study data repurposed dabrafenib, an anti-melanoma drug, for Parkinson's disease. Hum Mol Genet 2019; 27:3974-3985. [PMID: 30137437 PMCID: PMC6216208 DOI: 10.1093/hmg/ddy279] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2018] [Accepted: 07/17/2018] [Indexed: 12/21/2022] Open
Abstract
Parkinson's disease (PD) is a neurodegenerative disorder characterized by dopaminergic neuron loss. At present, there are no drugs that stop the progression of PD. As with other multifactorial genetic disorders, genome-wide association studies (GWASs) found multiple risk loci for PD, although their clinical significance remains uncertain. Here, we report the identification of candidate drugs for PD by a method using GWAS data and in silico databases. We identified 57 Food and Drug Administration-approved drug families as candidate neuroprotective drugs for PD. Among them, dabrafenib, which is known as a B-Raf kinase inhibitor and is approved for the treatment of malignant melanoma, showed remarkable cytoprotective effects in neurotoxin-treated SH-SY5Y cells and mice. Dabrafenib was found to inhibit apoptosis, and to enhance the phosphorylation of extracellular signal-regulated kinase (ERK), and inhibit the phosphorylation of c-Jun NH2-terminal kinase. Dabrafenib targets B-Raf, and we confirmed a protein-protein interaction between B-Raf and Rit2, which is coded by RIT2, a PD risk gene in Asians and Caucasians. In RIT2-knockout cells, the phosphorylation of ERK was reduced, and dabrafenib treatment improved the ERK phosphorylation. These data indicated that dabrafenib exerts protective effects against neurotoxicity associated with PD. By using animal model, we confirmed the effectiveness of this in silico screening method. Furthermore, our results suggest that this in silico drug screening system is useful in not only neurodegenerative diseases but also other common diseases such as diabetes mellitus and hypertension.
Collapse
Affiliation(s)
- Takeshi Uenaka
- Division of Neurology/Molecular Brain Science, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan
| | - Wataru Satake
- Division of Neurology/Molecular Brain Science, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan
| | - Pei-Chieng Cha
- Division of Neurology/Molecular Brain Science, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan
| | - Hideki Hayakawa
- Department of Neurology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
| | - Kousuke Baba
- Department of Neurology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
| | - Shiying Jiang
- Department of Neurology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
| | - Kazuhiro Kobayashi
- Division of Neurology/Molecular Brain Science, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan
| | - Motoi Kanagawa
- Division of Neurology/Molecular Brain Science, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan
| | - Yukinori Okada
- Department of Statistical Genetics, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.,Laboratory of Statistical Immunology, Immunology Frontier Research Center (WPI-IFReC), Osaka University, Suita, Osaka, Japan
| | - Hideki Mochizuki
- Department of Neurology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
| | - Tatsushi Toda
- Division of Neurology/Molecular Brain Science, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.,Department of Neurology, Graduate School of Medicine, The University of Tokyo, Bunkyo, Tokyo, Japan
| |
Collapse
|
31
|
Araki T, Yoshida F, Uemura T, Noda Y, Yoshimoto S, Kaiju T, Suzuki T, Hamanaka H, Baba K, Hayakawa H, Yabumoto T, Mochizuki H, Kobayashi S, Tanaka M, Hirata M, Sekitani T. Long-Term Implantable, Flexible, and Transparent Neural Interface Based on Ag/Au Core-Shell Nanowires. Adv Healthc Mater 2019; 8:e1900130. [PMID: 30946540 DOI: 10.1002/adhm.201900130] [Citation(s) in RCA: 21] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2019] [Revised: 03/11/2019] [Indexed: 12/11/2022]
Abstract
Neural interfaces enabling light transmittance rely on optogenetics to control and monitor specific neural activity, thereby facilitating deeper understanding of intractable diseases. This study reports the material strategy underlying an optogenetic neural interface comprising stretchable and transparent conductive tracks and capable of demonstrating high biocompatibility after long-term (5-month) implantation. Ag/Au core-shell nanowires contribute toward improving track performance in terms of stretchability (<60% strain), transparency (<83%), and electrical resistance (15 Ω sq-1 ). The neural interface integrated with gel-coated exterior microelectrodes preserves low impedance (1.1-3.2 Ω cm2 ) in a saline solution over the evaluated 5-month period. Besides the use of efficient conductive materials, surface treatment using antithrombogenic polymer tends to prevent the growth of granulation tissue, thereby facilitating clear monitoring of electrocorticograms (ECoG) in a rodent during chronic implantation. The flexible and transparent neural interface pathologically exhibits noncytotoxicity and low inflammatory response while efficiently recording evoked ECoG in a nonhuman primate via optogenetic stimulation. The proposed highly reliable interface can be employed in multifaceted approaches for translational research based on chronic implants.
Collapse
Affiliation(s)
- Teppei Araki
- Institute of Scientific and Industrial Research (ISIR) Osaka University Mihogaoka 8‐1 Ibaraki Osaka 567‐0047 Japan
| | - Fumiaki Yoshida
- Endowed Research Department of Clinical Neuroengineering Global Center for Medical Engineering and Informatics Osaka University 2‐2 Yamadaoka Suita Osaka 565‐0871 Japan
- Center for Information and Neural Networks National Institute of Information and Communications Technology (NICT) and Osaka University 1‐4 Yamadaoka Suita Osaka 565‐0871 Japan
- Department of Neurosurgery Graduate School of Medical Sciences Kyushu University 3‐1‐1, Maidashi, Higashi‐ku Fukuoka 812‐8582 Japan
- Japan Science and Technology Agency Precursory Research for Embryonic Science and Technology (PRESTO) 4‐1‐8 Honcho Kawaguchi Saitama 332‐0012 Japan
| | - Takafumi Uemura
- Institute of Scientific and Industrial Research (ISIR) Osaka University Mihogaoka 8‐1 Ibaraki Osaka 567‐0047 Japan
| | - Yuki Noda
- Institute of Scientific and Industrial Research (ISIR) Osaka University Mihogaoka 8‐1 Ibaraki Osaka 567‐0047 Japan
| | - Shusuke Yoshimoto
- Institute of Scientific and Industrial Research (ISIR) Osaka University Mihogaoka 8‐1 Ibaraki Osaka 567‐0047 Japan
| | - Taro Kaiju
- Center for Information and Neural Networks National Institute of Information and Communications Technology (NICT) and Osaka University 1‐4 Yamadaoka Suita Osaka 565‐0871 Japan
| | - Takafumi Suzuki
- Center for Information and Neural Networks National Institute of Information and Communications Technology (NICT) and Osaka University 1‐4 Yamadaoka Suita Osaka 565‐0871 Japan
| | - Hiroki Hamanaka
- Endowed Research Department of Clinical Neuroengineering Global Center for Medical Engineering and Informatics Osaka University 2‐2 Yamadaoka Suita Osaka 565‐0871 Japan
- Center for Information and Neural Networks National Institute of Information and Communications Technology (NICT) and Osaka University 1‐4 Yamadaoka Suita Osaka 565‐0871 Japan
| | - Kousuke Baba
- Department of Neurology Graduate School of Medicine Osaka University 2‐2 Yamadaoka Suita Osaka 565‐0871 Japan
| | - Hideki Hayakawa
- Department of Neurology Graduate School of Medicine Osaka University 2‐2 Yamadaoka Suita Osaka 565‐0871 Japan
| | - Taiki Yabumoto
- Department of Neurology Graduate School of Medicine Osaka University 2‐2 Yamadaoka Suita Osaka 565‐0871 Japan
| | - Hideki Mochizuki
- Department of Neurology Graduate School of Medicine Osaka University 2‐2 Yamadaoka Suita Osaka 565‐0871 Japan
| | - Shingo Kobayashi
- Institute for Materials Chemistry and Engineering (IMCE) Kyushu University 744 Motooka, Nishi‐ku Fukuoka 819‐0395 Japan
| | - Masaru Tanaka
- Institute for Materials Chemistry and Engineering (IMCE) Kyushu University 744 Motooka, Nishi‐ku Fukuoka 819‐0395 Japan
| | - Masayuki Hirata
- Endowed Research Department of Clinical Neuroengineering Global Center for Medical Engineering and Informatics Osaka University 2‐2 Yamadaoka Suita Osaka 565‐0871 Japan
- Center for Information and Neural Networks National Institute of Information and Communications Technology (NICT) and Osaka University 1‐4 Yamadaoka Suita Osaka 565‐0871 Japan
| | - Tsuyoshi Sekitani
- Institute of Scientific and Industrial Research (ISIR) Osaka University Mihogaoka 8‐1 Ibaraki Osaka 567‐0047 Japan
| |
Collapse
|
32
|
Kakuda K, Ikenaka K, Araki K, So M, Aguirre C, Kajiyama Y, Konaka K, Noi K, Baba K, Tsuda H, Nagano S, Ohmichi T, Nagai Y, Tokuda T, El-Agnaf OMA, Ogi H, Goto Y, Mochizuki H. Ultrasonication-based rapid amplification of α-synuclein aggregates in cerebrospinal fluid. Sci Rep 2019; 9:6001. [PMID: 30979935 PMCID: PMC6461702 DOI: 10.1038/s41598-019-42399-0] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2018] [Accepted: 03/13/2019] [Indexed: 12/19/2022] Open
Abstract
α-Synuclein aggregates, a key hallmark of the pathogenesis of Parkinson’s disease, can be amplified by using their seeding activity, and the evaluation of the seeding activity of cerebrospinal fluid (CSF) is reportedly useful for diagnosis. However, conventional shaking-based assays are time-consuming procedures, and the clinical significance of the diversity of seeding activity among patients remains to be clarified. Previously, we reported a high-throughput ultrasonication-induced amyloid fibrillation assay. Here, we adapted this assay to amplify and detect α-synuclein aggregates from CSF, and investigated the correlation between seeding activity and clinical indicators. We confirmed that this assay could detect α-synuclein aggregates prepared in vitro and also aggregates released from cultured cells. The seeding activity of CSF correlated with the levels of α-synuclein oligomers measured by an enzyme-linked immunosorbent assay. Moreover, the seeding activity of CSF from patients with Parkinson’s disease was higher than that of control patients. Notably, the lag time of patients with Parkinson’s disease was significantly correlated with the MIBG heart-to-mediastinum ratio. These findings showed that our ultrasonication-based assay can rapidly amplify misfolded α-synuclein and can evaluate the seeding activity of CSF.
Collapse
Affiliation(s)
- Keita Kakuda
- Department of Neurology, Graduate School of Medicine, Osaka University, Yamadaoka 2-2, Suita, Osaka, 565-0871, Japan
| | - Kensuke Ikenaka
- Department of Neurology, Graduate School of Medicine, Osaka University, Yamadaoka 2-2, Suita, Osaka, 565-0871, Japan
| | - Katsuya Araki
- Department of Neurology, Graduate School of Medicine, Osaka University, Yamadaoka 2-2, Suita, Osaka, 565-0871, Japan
| | - Masatomo So
- Institute for Protein Research, Osaka University, Yamadaoka 3-2, Suita, Osaka, 565-0871, Japan
| | - César Aguirre
- Institute for Protein Research, Osaka University, Yamadaoka 3-2, Suita, Osaka, 565-0871, Japan
| | - Yuta Kajiyama
- Department of Neurology, Graduate School of Medicine, Osaka University, Yamadaoka 2-2, Suita, Osaka, 565-0871, Japan
| | - Kuni Konaka
- Department of Neurology, Graduate School of Medicine, Osaka University, Yamadaoka 2-2, Suita, Osaka, 565-0871, Japan
| | - Kentaro Noi
- Department of Precision Science and Technology, Graduate School of Engineering, Osaka University, Yamadaoka 2-1, Suita, Osaka, 565-0871, Japan
| | - Kousuke Baba
- Department of Neurology, Graduate School of Medicine, Osaka University, Yamadaoka 2-2, Suita, Osaka, 565-0871, Japan
| | - Hiroshi Tsuda
- Department of Neurology, Graduate School of Medicine, Osaka University, Yamadaoka 2-2, Suita, Osaka, 565-0871, Japan
| | - Seiichi Nagano
- Department of Neurology, Graduate School of Medicine, Osaka University, Yamadaoka 2-2, Suita, Osaka, 565-0871, Japan
| | - Takuma Ohmichi
- Department of Neurology, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kamikyo-ku, Kyoto, 602-8566, Japan
| | - Yoshitaka Nagai
- Department of Neurotherapeutics, Graduate school of Medicine, Osaka University, Yamadaoka 2-2, Suita, Osaka, 565-0871, Japan
| | - Takahiko Tokuda
- Department of Molecular Pathobiology of Brain Diseases, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kamikyo-ku, Kyoto, 602-8566, Japan
| | - Omar M A El-Agnaf
- Life Sciences Division, College of Science and Engineering, Hamad Bin Khalifa University (HBKU), Education City, Qatar
| | - Hirotsugu Ogi
- Department of Precision Science and Technology, Graduate School of Engineering, Osaka University, Yamadaoka 2-1, Suita, Osaka, 565-0871, Japan
| | - Yuji Goto
- Institute for Protein Research, Osaka University, Yamadaoka 3-2, Suita, Osaka, 565-0871, Japan
| | - Hideki Mochizuki
- Department of Neurology, Graduate School of Medicine, Osaka University, Yamadaoka 2-2, Suita, Osaka, 565-0871, Japan.
| |
Collapse
|
33
|
Yabumoto T, Yoshida F, Miyauchi H, Baba K, Tsuda H, Ikenaka K, Hayakawa H, Koyabu N, Hamanaka H, Papa SM, Hirata M, Mochizuki H. MarmoDetector: A novel 3D automated system for the quantitative assessment of marmoset behavior. J Neurosci Methods 2019; 322:23-33. [PMID: 30946879 DOI: 10.1016/j.jneumeth.2019.03.016] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2018] [Revised: 03/28/2019] [Accepted: 03/28/2019] [Indexed: 11/28/2022]
Abstract
BACKGROUND Callithrix jacchus, generally known as the common marmoset, has recently garnered interest as an experimental primate model for better understanding the basis of human social behavior, architecture and function. Modelling human neurological and psychological diseases in marmosets can enhance the knowledge obtained from rodent research for future pre-clinical studies. Hence, comprehensive and quantitative assessments of marmoset behaviors are crucial. However, systems for monitoring and analyzing marmoset behaviors have yet to be established. NEW METHOD In this paper, we present a novel multimodal system, MarmoDetector, for the automated 3D analysis of marmoset behavior under freely moving conditions. MarmoDetector allows the quantitative assessment of marmoset behaviors using computerised tracking analysis techniques that are based on a Kinect system equipped with video recordings, infrared images and depth analysis. RESULTS Using MarmoDetector, we assessed behavioral circadian rhythms continuously over several days in home cages. In addition, MarmoDetector detected acute, transient complex behaviors of alcohol injected marmosets. COMPARISON TO EXISTING METHOD Compared to 2D recording, MarmoDetector detects activities more precisely and is very sensitive as we could detect behavioral defects specifically induced by alcohol administration. CONCLUSION MarmoDetector facilitates the rapid and accurate analysis of marmoset behavior and will enhance research on the neural basis of brain disorders.
Collapse
Affiliation(s)
- Taiki Yabumoto
- Department of Neurology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan
| | - Fumiaki Yoshida
- Department of Neurological Diagnosis and Restoration, Graduat School of Medicine, Osaka University, Suita, Osaka, Japan; Department of Neurosurgery, Osaka University Medical School, Suita, Osaka, Japan; Department of Anatomy & Physiology, Faculty of Medicine, Saga University, Saga, Japan; Japan Science and Technology Agency, PRESTO, Japan
| | | | - Kousuke Baba
- Department of Neurology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan; Department of Advanced Hybrid Medicine, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan
| | - Hiroshi Tsuda
- Department of Neurology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan
| | - Kensuke Ikenaka
- Department of Neurology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan
| | - Hideki Hayakawa
- Department of Neurology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan
| | - Nozomu Koyabu
- The Institute of Large Laboratory Animal Sciences, Center of Medical Innovation and Translational Research, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan
| | - Hiroki Hamanaka
- Department of Neurological Diagnosis and Restoration, Graduat School of Medicine, Osaka University, Suita, Osaka, Japan
| | - Stella M Papa
- Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA; Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA
| | - Masayuki Hirata
- Department of Neurological Diagnosis and Restoration, Graduat School of Medicine, Osaka University, Suita, Osaka, Japan; Department of Neurosurgery, Osaka University Medical School, Suita, Osaka, Japan; Center for Information and Neural Networks, National Institute of Information and Communications Technology and Osaka University, Osaka, Japan.
| | - Hideki Mochizuki
- Department of Neurology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
| |
Collapse
|
34
|
Ohkura N, Atsumi G, Ohnishi K, Baba K, Taniguchi M. Possible antithrombotic effects of Angelica keiskei (Ashitaba). Pharmazie 2018; 73:315-317. [PMID: 29880082 DOI: 10.1691/ph.2018.8370] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 09/29/2022]
Abstract
Angelica keiskei Koidzumi (Ashitaba) is a large perennial herb that is native to the Pacific coast of Japan, and it has recently become popular as herbal medicine, dietary supplement and health food in Asian countries. The structures of various constituents isolated from Ashitaba such as chalcones, flavanones and coumarins have been precisely characterized, and many of them have bioactivities. A recent study clarified that Angelica keiskei exerts actions that lead to the prevention of thrombosis. Here, we introduce the possibility that ingesting Ashitaba could help to prevent thrombotic diseases.
Collapse
|
35
|
Ohkura N, Ohnishi K, Taniguchi M, Nakayama A, Usuba Y, Fujita M, Fujii A, Ishibashi K, Baba K, Atsumi G. Anti-platelet effects of chalcones from Angelica keiskei Koidzumi (Ashitaba) in vivo. Pharmazie 2018; 71:651-654. [PMID: 29441970 DOI: 10.1691/ph.2016.6678] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 09/29/2022]
Abstract
Angelica keiskei Koidzumi (Ashitaba) is a traditional folk medicine that is also regarded in Japan as a health food with potential antithrombotic properties. The ability of the major chalcones, xanthoangelol (XA) and 4-hydroxyderricin (4-HD) extracted from Ashitaba roots to inhibit platelet aggregation activity in vitro was recently determined. However, the anti-platelet activities of Ashitaba chalcones in vivo have remained unclear. The present study examines the anti-platelet effects of Ashitaba exudate and its constituent chalcones using mouse tail-bleeding models that reflect platelet aggregation in vivo. Ashitaba exudate and the major chalcone subtype XA, suppressed the lipopolysaccharide (LPS)-induced shortening of mouse tail bleeding. However, trace amounts of other Ashitaba chalcone subtypes including xanthoangelols B (XB), D (XD), E (XE) and F (XF) did not affect tail bleeding. These results suggest that the major chalcone subtype in Ashitaba, XA, has anti-platelet-activities in vivo.
Collapse
|
36
|
Murakami TC, Mano T, Saikawa S, Horiguchi SA, Shigeta D, Baba K, Sekiya H, Shimizu Y, Tanaka KF, Kiyonari H, Iino M, Mochizuki H, Tainaka K, Ueda HR. A three-dimensional single-cell-resolution whole-brain atlas using CUBIC-X expansion microscopy and tissue clearing. Nat Neurosci 2018; 21:625-637. [DOI: 10.1038/s41593-018-0109-1] [Citation(s) in RCA: 172] [Impact Index Per Article: 28.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2017] [Accepted: 02/06/2018] [Indexed: 12/12/2022]
|
37
|
Inoue N, Ogura S, Kasai A, Nakazawa T, Ikeda K, Higashi S, Isotani A, Baba K, Mochizuki H, Fujimura H, Ago Y, Hayata-Takano A, Seiriki K, Shintani Y, Shintani N, Hashimoto H. Knockdown of the mitochondria-localized protein p13 protects against experimental parkinsonism. EMBO Rep 2018; 19:embr.201744860. [PMID: 29371327 DOI: 10.15252/embr.201744860] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2017] [Revised: 12/15/2017] [Accepted: 12/21/2017] [Indexed: 12/21/2022] Open
Abstract
Mitochondrial dysfunction in the nigrostriatal dopaminergic system is a critical hallmark of Parkinson's disease (PD). Mitochondrial toxins produce cellular and behavioural dysfunctions resembling those in patients with PD Causative gene products for familial PD play important roles in mitochondrial function. Therefore, targeting proteins that regulate mitochondrial integrity could provide convincing strategies for PD therapeutics. We have recently identified a novel 13-kDa protein (p13) that may be involved in mitochondrial oxidative phosphorylation. In the current study, we examine the mitochondrial function of p13 and its involvement in PD pathogenesis using mitochondrial toxin-induced PD models. We show that p13 overexpression induces mitochondrial dysfunction and apoptosis. p13 knockdown attenuates toxin-induced mitochondrial dysfunction and apoptosis in dopaminergic SH-SY5Y cells via the regulation of complex I. Importantly, we generate p13-deficient mice using the CRISPR/Cas9 system and observe that heterozygous p13 knockout prevents toxin-induced motor deficits and the loss of dopaminergic neurons in the substantia nigra. Taken together, our results suggest that manipulating p13 expression may be a promising avenue for therapeutic intervention in PD.
Collapse
Affiliation(s)
- Naoki Inoue
- Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka, Japan.,Interdisciplinary Program for Biomedical Sciences, Institute for Academic Initiatives, Osaka University, Suita, Osaka, Japan.,Research Fellowships for Young Scientists of the Japan Society for the Promotion of Science, Chiyoda, Tokyo, Japan
| | - Sae Ogura
- Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka, Japan
| | - Atsushi Kasai
- Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka, Japan
| | - Takanobu Nakazawa
- Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka, Japan.,Department of Pharmacology, Graduate School of Dentistry, Osaka University, Suita, Osaka, Japan
| | - Kazuya Ikeda
- Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka, Japan
| | - Shintaro Higashi
- Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka, Japan
| | - Ayako Isotani
- Animal Resource Center for Infectious Diseases, Immunology Frontier Research Center, Osaka University, Suita, Osaka, Japan.,Graduate School of Biological Sciences, Nara Institute of Science and Technology, Ikoma, Nara, Japan
| | - Kousuke Baba
- Department of Neurology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan
| | - Hideki Mochizuki
- Department of Neurology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan
| | | | - Yukio Ago
- Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka, Japan
| | - Atsuko Hayata-Takano
- Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka, Japan.,Molecular Research Center for Children's Mental Development, United Graduate School of Child Development, Osaka University Kanazawa University Hamamatsu University School of Medicine Chiba University and University of Fukui, Suita, Osaka, Japan
| | - Kaoru Seiriki
- Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka, Japan.,Interdisciplinary Program for Biomedical Sciences, Institute for Academic Initiatives, Osaka University, Suita, Osaka, Japan
| | - Yusuke Shintani
- Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka, Japan
| | - Norihito Shintani
- Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka, Japan
| | - Hitoshi Hashimoto
- Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka, Japan .,Molecular Research Center for Children's Mental Development, United Graduate School of Child Development, Osaka University Kanazawa University Hamamatsu University School of Medicine Chiba University and University of Fukui, Suita, Osaka, Japan.,iPS Cell-based Research Project on Brain Neuropharmacology and Toxicology, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka, Japan.,Division of Bioscience, Institute for Datability Science, Osaka University, Suita, Osaka, Japan
| |
Collapse
|
38
|
Nakazato Y, Takaba M, Abe Y, Yoshida Y, Ono Y, Yoshizawa S, Nakamura H, Kawana F, Suganuma T, Kato T, Baba K. Accuracy of newly developed portable PSG device for detection of sleep bruxism-related masseter EMG muscle activity. Sleep Med 2017. [DOI: 10.1016/j.sleep.2017.11.693] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
39
|
Takemoto Y, Inaba S, Zhang L, Baba K, Hagihara K, Fukada SI. An herbal medicine, Go-sha-jinki-gan (GJG), increases muscle weight in severe muscle dystrophy model mice. Clinical Nutrition Experimental 2017. [DOI: 10.1016/j.yclnex.2017.08.003] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
40
|
Kaneko K, Miyamoto Y, Tsukuura R, Sasa K, Akaike T, Fujii S, Yoshimura K, Nagayama K, Hoshino M, Inoue S, Maki K, Baba K, Chikazu D, Kamijo R. 8-Nitro-cGMP is a promoter of osteoclast differentiation induced by RANKL. Nitric Oxide 2017; 72:46-51. [PMID: 29183803 DOI: 10.1016/j.niox.2017.11.006] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2017] [Revised: 11/07/2017] [Accepted: 11/17/2017] [Indexed: 10/18/2022]
Abstract
Osteoclasts are multinucleated giant cells differentiated from monocyte-macrophage-lineage cells under stimulation of receptor activator of nuclear factor κ-B (RANK) ligand (RANKL) produced by osteoblasts and osteocytes. Although it has been reported that nitric oxide (NO) and reactive oxygen species (ROS) are involved in this process, the mechanism by which these labile molecules promote osteoclast differentiation are not fully understood. In this study, we investigated the formation and function of 8-nitro-cGMP, a downstream molecule of NO and ROS, in the process of osteoclast differentiation in vitro. 8-Nitro-cGMP was detected in mouse bone marrow macrophages and osteoclasts differentiated from macrophages in the presence of RANKL. Inhibition of NO synthase suppressed the formation of 8-nitro-cGMP as well as RANKL-induced osteoclast differentiation from macrophages. On the other hand, RANKL-induced osteoclast differentiation was promoted by addition of 8-nitro-cGMP to the cultures. In addition, 8-nitro-cGMP enhanced the mRNA expression of RANK, the receptor for RANKL. However, 8-bromo-cGMP, a membrane-permeable derivative of cGMP, did not have an effect on either RANKL-induced osteoclast differentiation or expression of the RANK gene. These results suggest that 8-nitro-cGMP is a novel positive regulator of osteoclast differentiation, which might help to explain the roles of NO and ROS in osteoclast differentiation.
Collapse
Affiliation(s)
- K Kaneko
- Department of Biochemistry, Showa University School of Dentistry, Japan; Department of Oral and Maxillofacial Surgery, Tokyo Medical University, Japan
| | - Y Miyamoto
- Department of Biochemistry, Showa University School of Dentistry, Japan.
| | - R Tsukuura
- Department of Biochemistry, Showa University School of Dentistry, Japan; Department of Oral and Maxillofacial Surgery, Tokyo Medical University, Japan
| | - K Sasa
- Department of Biochemistry, Showa University School of Dentistry, Japan
| | - T Akaike
- Department of Environmental Health Sciences and Molecular Toxicology, Tohoku University Graduate School of Medicine, Japan
| | - S Fujii
- Department of Environmental Health Sciences and Molecular Toxicology, Tohoku University Graduate School of Medicine, Japan
| | - K Yoshimura
- Department of Biochemistry, Showa University School of Dentistry, Japan
| | - K Nagayama
- Department of Biochemistry, Showa University School of Dentistry, Japan; Department of Orthodontics, Showa University School of Dentistry, Japan
| | - M Hoshino
- Department of Prosthodontics, Showa University School of Dentistry, Japan
| | - S Inoue
- Department of Prosthodontics, Showa University School of Dentistry, Japan
| | - K Maki
- Department of Orthodontics, Showa University School of Dentistry, Japan
| | - K Baba
- Department of Prosthodontics, Showa University School of Dentistry, Japan
| | - D Chikazu
- Department of Oral and Maxillofacial Surgery, Tokyo Medical University, Japan
| | - R Kamijo
- Department of Biochemistry, Showa University School of Dentistry, Japan
| |
Collapse
|
41
|
Hayakawa H, Baba K, Takeuchi T, Choong C, Nagano S, Nagai Y, Mochizuki H. In vitro assessment of extracellular alpha-synuclein secretion. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.664] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
42
|
Okubo K, Hashiguchi K, Takeda T, Baba K, Kitagoh H, Miho H, Tomomatsu H, Yamaguchi S, Odani M, Yamamotoya H. A randomized controlled phase II clinical trial comparing ONO-4053, a novel DP1 antagonist, with a leukotriene receptor antagonist pranlukast in patients with seasonal allergic rhinitis. Allergy 2017; 72:1565-1575. [PMID: 28378369 PMCID: PMC5638107 DOI: 10.1111/all.13174] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/28/2017] [Indexed: 11/30/2022]
Abstract
Background Prostaglandin D2 (PGD2) is primarily produced by mast cells and is contributing to the nasal symptoms including nasal obstruction and rhinorrhea. Objective This study aimed to evaluate the efficacy and safety of a novel PGD2 receptor 1 (DP1) antagonist, ONO‐4053, in patients with seasonal allergic rhinitis (SAR). Methods This study was a multicenter, randomized, double‐blind, parallel‐group study of patients with SAR. Following a one‐week period of placebo run‐in, patients who met the study criteria were randomized to either the ONO‐4053, leukotriene receptor antagonist pranlukast, or placebo group for a two‐week treatment period. A total of 200 patients were planned to be randomly assigned to receive ONO‐4053, pranlukast, or placebo in a 2:2:1 ratio. Nasal and eye symptoms were evaluated. Results Both ONO‐4053 and pranlukast had higher efficacy than placebo on all nasal and eye symptoms. ONO‐4053 outperformed pranlukast in a total of three nasal symptom scores (T3NSS) as well as in individual scores for sneezing, rhinorrhea, and nasal itching. For T3NSS, the Bayesian posterior probabilities that pranlukast was better than placebo and ONO‐4053 was better than pranlukast were 70.0% and 81.6%, respectively, suggesting that ONO‐4053 has a higher efficacy compared with pranlukast. There was no safety‐related issue in this study. Conclusions We demonstrated that the efficacy of ONO‐4053 was greater than that of pranlukast with a similar safety profile. This study indicates the potential of ONO‐4053 for use as a treatment for SAR (JapicCTI‐142706).
Collapse
Affiliation(s)
- K. Okubo
- Department of Otorhinolaryngology; Nippon Medical School; Tokyo Japan
| | - K. Hashiguchi
- Department of Otorhinolaryngology; Futaba Clinic; Tokyo Japan
- Medical Corporation Shinanokai; Samoncho Clinic; Tokyo Japan
| | - T. Takeda
- Department of Otorhinolaryngology; Takeda Clinic; Saitama Japan
| | - K. Baba
- Department of Otorhinolaryngology; Takasaka Clinic; Saitama Japan
| | - H. Kitagoh
- Department of Otorhinolaryngology; Kitagoh Clinic; Kanagawa Japan
| | - H. Miho
- Department of Otorhinolaryngology; Miho Clinic; Kanagawa Japan
| | - H. Tomomatsu
- Department of Otorhinolaryngology; Tomomatsu Clinic; Tokyo Japan
| | - S. Yamaguchi
- Discovery Research Laboratories III; Ono Pharmaceutical Co., Ltd.; Osaka Japan
| | - M. Odani
- Data Science; Ono Pharmaceutical Co., Ltd.; Osaka Japan
| | - H. Yamamotoya
- Translational Science; Ono Pharmaceutical Co., Ltd.; Osaka Japan
| |
Collapse
|
43
|
Uehara T, Choong C, Hayakawa H, Kasahara Y, Nagata T, Yokota T, Baba K, Nakamori M, Obika S, Mochizuki H. Antisense oligonucleotides containing amido-bridged nucleic acid reduce SNCA expression and improve motor function in Parkinson's disease animal models. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.2950] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
44
|
Uenaka T, Satake W, Cha P, Kobayashi K, Kanagawa M, Hayakawa H, Baba K, Okada Y, Mochizuki H, Toda T. In silico drug screening identified a novel disease-modifying drug for Parkinson’s disease. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.2951] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
45
|
Yabumoto T, Yoshida F, Baba K, Hayakawa H, Hamanaka H, Hirata M, Mochizuki H. A novel method for behavioral assessments of the common marmoset, marmodetector, detects general natural movement and changes in motor behavior. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.2640] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
46
|
Araki K, Naoto Y, Ikenaka K, Hayakawa H, Baba K, Nagai Y, Mochizuki H. Fine structure analysis of alpha-synuclein aggregates in the patient’s brain with synchrotron radiation. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.616] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
47
|
Choong C, Sasaki T, Hayakawa H, Baba K, Hirata Y, Uesato S, Mochizuki H. Small-molecule inhibitors of P53/negative regulator-interaction protect dopaminergic neurons against MPP +/MPTP-induced neurotoxicity. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.632] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
48
|
Flege S, Hatada R, Derepa A, Dietz C, Ensinger W, Baba K. Note: Sample holder with open area for increased deposition rate in plasma immersion ion implantation and deposition. Rev Sci Instrum 2017; 88:096106. [PMID: 28964196 DOI: 10.1063/1.4995080] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
A sample holder with a large open area offers several benefits when used in the process of plasma immersion ion implantation and deposition in which the plasma is generated by a high voltage applied to the sample holder: The ignition voltage of the plasma is lower, and the deposition rate can be several times higher than in the case of a normal plate-like holder. There is a more pronounced edge effect regarding the film thickness. Other film properties are also affected; for diamond-like carbon films, the film structure exhibits more disorder. The hardness of the samples is similar, with the surfaces of the samples being very smooth.
Collapse
Affiliation(s)
- S Flege
- Department of Materials Science, Technische Universität Darmstadt, 64287 Darmstadt, Germany
| | - R Hatada
- Department of Materials Science, Technische Universität Darmstadt, 64287 Darmstadt, Germany
| | - A Derepa
- Department of Materials Science, Technische Universität Darmstadt, 64287 Darmstadt, Germany
| | - C Dietz
- Department of Materials Science, Technische Universität Darmstadt, 64287 Darmstadt, Germany
| | - W Ensinger
- Department of Materials Science, Technische Universität Darmstadt, 64287 Darmstadt, Germany
| | - K Baba
- Graduate School of Engineering, Nagasaki University, Nagasaki 852-8521, Japan
| |
Collapse
|
49
|
Tutschek B, Blaas HGK, Abramowicz J, Baba K, Deng J, Lee W, Merz E, Platt L, Pretorius D, Timor-Tritsch IE, Gindes L. Three-dimensional ultrasound imaging of the fetal skull and face. Ultrasound Obstet Gynecol 2017; 50:7-16. [PMID: 28229509 DOI: 10.1002/uog.17436] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/30/2016] [Revised: 02/06/2017] [Accepted: 02/14/2017] [Indexed: 06/06/2023]
Affiliation(s)
- B Tutschek
- Prenatal Zurich, Zürich, Switzerland
- Medical Faculty, Heinrich Heine University, Düsseldorf, Germany
| | - H-G K Blaas
- Department of Laboratory Medicine, Children's and Women's Health, Norwegian University of Science and Technology, National Center for Fetal Medicine, St Olavs Hospital, Trondheim, Norway
| | - J Abramowicz
- Department of Obstetrics and Gynecology, University of Chicago, Chicago, IL, USA
| | - K Baba
- Saitama Medical Center, Saitama Medical University, Kawagoe, Japan
| | - J Deng
- University College London, London, UK
| | - W Lee
- Baylor College of Medicine, Obstetrics & Gynecology, Houston, TX, USA
| | - E Merz
- Krankenhaus Nordwest - Centre for Prenatal Diagnosis and Therapy, Frankfurt, Germany
| | - L Platt
- Department of Obstetrics and Gynecology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
| | - D Pretorius
- Department of Radiology, University of California San Diego, CA, USA
| | - I E Timor-Tritsch
- Department of Obstetrics and Gynecology, NYU School of Medicine, New York, NY, USA
| | - L Gindes
- Department of Obstetrics and Gynecology, Wolfson Medical Center, and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| |
Collapse
|
50
|
Fueki K, Baba K. Shortened dental arch and prosthetic effect on oral health-related quality of life: a systematic review and meta-analysis. J Oral Rehabil 2017; 44:563-572. [DOI: 10.1111/joor.12511] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/26/2017] [Indexed: 11/28/2022]
Affiliation(s)
- K. Fueki
- Removable Partial Prosthodontics; Graduate School of Medical and Dental Sciences; Tokyo Medical and Dental University (TMDU); Tokyo Japan
| | - K. Baba
- Department of Prosthodontics; Showa University; Tokyo Japan
| |
Collapse
|